



“Pain Tears Me Apart”

**Challenges and Progress in Ensuring the Right to Palliative Care
in Morocco**

Copyright © 2015 Human Rights Watch

All rights reserved.

Printed in the United States of America

ISBN: 978-1-6231-33207

Cover design by Rafael Jimenez

Human Rights Watch defends the rights of people worldwide. We scrupulously investigate abuses, expose the facts widely, and pressure those with power to respect rights and secure justice. Human Rights Watch is an independent, international organization that works as part of a vibrant movement to uphold human dignity and advance the cause of human rights for all.

Human Rights Watch is an international organization with staff in more than 40 countries, and offices in Amsterdam, Beirut, Berlin, Brussels, Chicago, Geneva, Goma, Johannesburg, London, Los Angeles, Moscow, Nairobi, New York, Paris, San Francisco, Sydney, Tokyo, Toronto, Tunis, Washington DC, and Zurich.

For more information, please visit our website: <http://www.hrw.org>



“Pain Tears Me Apart”

Challenges and Progress in Ensuring the Right to Palliative Care in Morocco

- Summary 1**
- Key Recommendations 8**
 - To the Government of Morocco 8
- Methodology 9**
- I. Background..... 11**
 - Importance of Palliative Care and Pain Relief11
 - Global and Regional Availability of Palliative Care15
 - Background on Morocco’s Healthcare System 20
 - History of Palliative Care in Morocco 25
- II. Palliative Care in Morocco and Patients’ Experiences 26**
 - Availability of Palliative Care in Morocco 26
 - Experience of People in Need of Pain Treatment 30
- III. Barriers to Accessing Palliative Care in Morocco..... 37**
 - Integrating Palliative Care into the Healthcare System..... 38
 - Integrating Palliative Care into Healthcare Financing 43
 - Palliative Care Education for Healthcare Workers 45
 - Medicine Availability 52
- IV. Morocco’s Obligation to Improve Palliative Care..... 64**
 - National Law 64
 - Right to Health 64
 - Palliative Care and the Right to Health 66
 - Pain Treatment Medication and the Right to Health 67
 - Pain Treatment and the Right to Be Free from Cruel, Inhuman, or Degrading Treatment 68
- V. Full Recommendations 71**
 - In the Area of Integrating Palliative Care into the Structure of the Healthcare System 72
 - In the Area of Integrating Palliative Care into Healthcare Financing..... 73

In the Area of Education.....	73
In the Area of Medicine Availability	74
Acknowledgments.....	76
Appendix: Comparison of Neuropathic Pain Medicines with the WHO and Moroccan Essential Medicines Lists.....	77

Summary

Because of the pain I couldn't sleep. I couldn't talk to my friends. I wanted to crush my head against the wall and shake.... My pain tears me apart.

—Adil Akram, 29, who battled cancer in his leg for years, Rabat, October 1, 2014

In 2013, Zayan Ebrahim (pseudonym) was a college student and restaurant chef in a city about 250 kilometers from Rabat, Morocco's capital, when he began experiencing pain. After two local physicians misdiagnosed and treated him for hemorrhoids, the pain became so intense that, in his words, it began to drive him "crazy." "I'm not sleeping," he said. "Even when I am very tired, I only sleep for one hour [at a time]. Then I wake up because of the pain."

On the advice of a local pharmacist, he traveled to Rabat to seek further medical help. A doctor there discovered that he had colon cancer. Zayan began treatment at the National Oncology Institute where he was also referred to the palliative care service for pain management. There, his pain was finally properly assessed and treated.

But the months of suffering had taken a toll on Zayan. His health had deteriorated and he had lost almost 30 kilograms in weight before receiving proper treatment. As he told Human Rights Watch of his experience, Zayan repeatedly broke down in tears and occasionally became angry at how the healthcare system had failed him.

While the palliative care service in Rabat was able to finally control his pain, Zayan still faces challenges. Because neither cancer treatment nor palliative care is available in his hometown, he has been forced to uproot his life and move into an apartment of a friend who lives in Rabat.

Every year, more than 150,000 Moroccans face advanced—and often incurable—chronic illnesses such as cancer; heart, lung, or renal disease; dementia; and AIDS. Over 62,000

Moroccans, including 6,000 children, suffering from these illnesses will experience debilitating symptoms such as pain, breathlessness, and depression.

These symptoms can often be treated well through palliative care, a health service that focuses on relieving them and ensuring that people with life-limiting illnesses and their loved-ones can enjoy the best possible quality of life during the course of their disease up until their last moments.

Ensuring the availability of palliative care has become an increasingly important global health priority in recent years. As populations age and the prevalence of chronic illnesses increases in most low and middle income countries, the need for palliative care has risen drastically. The World Health Organization (WHO) estimates that more than 40 million people require palliative care annually at the end of life.

Morocco is no exception. Non-communicable diseases such as cancer, heart disease, diabetes, and respiratory illnesses account for 75 percent of an estimated 206,000 annual deaths. And the burden of chronic illness is likely to rise. The percentage of people over 65, the segment of the population most affected by these illnesses, is expected to nearly double over the next 15 years. In that same period, the incidence of cancer is expected to nearly triple.

This report identifies challenges people with life-limiting illnesses in Morocco face accessing palliative care, with a special focus on access to pain treatment. The report is based on research Human Rights Watch conducted in Morocco from September 2014 to January 2015, interviewing 85 individuals, including healthcare workers, government officials, and patients and their family members in five regions. We also reviewed relevant legislation, insurance policies, medicines lists, and other policy documents.

Our research found that the government of Morocco has taken several positive steps in recent years to develop palliative care services and to expand access to pain medicines. Significantly, the government released two national health policies that together set out a vision for the development of palliative care; reformed the undergraduate medical curriculum to include a module on pain and palliative care; and removed a large regulatory barrier to accessing opioid analgesics—strong pain medications that are indispensable for pain management.

However, the availability of palliative care in Morocco is very limited. At present, only two public hospitals in the country—both tertiary level cancer hospitals—have established palliative care units. As a result, cancer patients have some access to palliative care but often have to travel long distances to get it, a great burden on them that often becomes insurmountable as their disease progresses and enters the final stages.

No palliative care units are available for people with non-oncological conditions, even though the WHO and Worldwide Hospice and Palliative Care Alliance estimate that over 70 percent of adults in need of palliative care from the WHO's Eastern Mediterranean region have chronic illnesses other than cancer. In other words, around 40,000 adults in Morocco require palliative care each year for conditions other than cancer.

Human Rights Watch was unable to identify any palliative care services at lower levels of the healthcare system, such as regional, provincial, and local hospitals, even though these healthcare facilities are closest to where people who require palliative care live.

Although some healthcare providers, particularly tertiary level hospitals, have integrated palliative care interventions into their general practice, Human Rights Watch believes that to be the exception, as most facilities simply do not have staff trained in palliative care or access to key palliative care medications such as morphine.

Moreover, although the use of opioid analgesics is increasing in Morocco, government data suggests that there is still a major gap in the treatment of moderate to severe pain. The amount of opioids used in Morocco is only sufficient to provide pain relief to one in five patients with cancer or AIDS, without taking into account the opioid needs of patients with illnesses such as heart and lung disease or diabetes. The result is that tens of thousands of Moroccans with life-limiting illnesses pass their last weeks and months in great unnecessary suffering.

Despite the severe suffering he faced due to untreated pain, Zayan is one of the privileged Moroccans who eventually did gain access to palliative care, even if delayed and far from his home.

The WHO considers palliative care to be an essential health service and has urged countries to ensure that it is integrated into all levels of the healthcare system. It has recommended that countries implement health and health financing policies to promote it, ensure adequate training of health professionals, make available essential palliative care medicines, including opioid analgesics, and encourage research to assess needs and identify standards and models of care. As palliative care does not need expensive equipment or medications, it can generally be provided at relatively low cost. A World Health Assembly (WHA) resolution on palliative care unanimously adopted on May 23, 2014, closely mirrors these recommendations.

Morocco has taken important steps in each of the four areas the WHO and WHA identifies as fundamental for the development of palliative care. However, our research shows that much remains to be done.

Policy: The government has included specific palliative care goals in the Sectoral Health Strategy (SHS) 2012-2016, Morocco’s national health strategy, as well as in its National Cancer Prevention and Control Plan (NCPCP) 2010-2019. The documents call for the creation of palliative care networks; the development of external palliative care consultations; and the institutionalization of pain treatment at all levels of the healthcare system—all very much in line with WHO and WHA recommendations.

However, neither strategy appears designed to succeed. Neither sets a specific timeline nor identifies clearly what agencies are responsible for implementing the measures. Nor does it appear that the government has a clear process for tracking implementation progress. While the NCPCP breaks down its overall objectives into specific action points, the SHS only contains broad measures. The SHS does not contain a budget; palliative care makes up just 1 percent of the NCPCP’s overall budget.

Given the above, it is perhaps not surprising that Human Rights Watch analysis of the implementation effort has found that progress has been uneven and limited in many areas.

Key findings include:

- Little progress has been made to date developing the decentralized palliative care network that the NCPCP envisions. While a palliative care center was created in Casablanca, none have been established anywhere else in the country (despite plans in the NCPCP to begin building centers in Fez and Marrakesh in 2011 and 2012, respectively);
- Opioid analgesics remain largely unavailable outside tertiary health facilities. The controlled substances law has been amended to increase the maximum prescription period for opioid analgesics, but few steps have been taken to counter physicians' and pharmacists' fears and misconceptions around these medicines or to increase the number of physicians with prescription privileges; and
- Progress towards decentralizing pain management has been limited. Our research suggests pain management committees at regional and provincial hospitals have either not yet been established or are not functioning effectively.

Insurance: Since 2005, the government has instituted two major health insurance reforms: a compulsory health insurance program (*Assurance Maladie Obligatoire* or AMO) for salaried public and private sector employees; and a public insurance scheme (*Regime d'Assistance Medicale* or RAMED) for the poor. These insurance programs cover close to 50 percent of Moroccans. Both insurance schemes cover the provision of palliative care and a fairly comprehensive set of essential palliative care medicines. However, in practice, this insurance coverage is not effective as very few healthcare providers offer palliative care and RAMED does not cover medications for outpatients.

Education: In September 2015, Morocco's medical schools will begin teaching a mandatory 20-hour segment on palliative care for 5th year medical students, a major step toward ensuring all physicians have at least basic palliative care knowledge and skills. However, continuing medical education programs and intermediate and advanced training opportunities in palliative care remain limited and only meet a fraction of the need.

Medicine availability: In 2013, Morocco changed its controlled substance law to increase the number of days a prescription for an opioid analgesic can cover from 7 to 28 days, removing a key barrier to the availability of these medicines. The seven-day limitation

meant that patients who required opioid analgesics or their relatives had to travel to their physician every single week to obtain and fill a new prescription.

Our analysis of Morocco’s drug regulations shows that while they are more restrictive than required by the United Nations drug conventions and generate additional work for physicians, pharmacists, and hospital administrations, the requirements do not appear to be excessively burdensome.

However, use of opioid analgesics remains very limited. Few pharmacies and hospitals stock oral morphine and only a small fraction of physicians have the ability to prescribe opioids. The government itself has identified physician’s exaggerated fear of the risks associated with opioid analgesics—known as opiophobia or morphineophobia—as a significant barrier to adequate prescribing. Indeed, we found that many of the physicians and pharmacists we interviewed had misconceptions about opioid analgesics.

Problematically, Morocco’s controlled substances law itself appears to stigmatize these medications by labeling them “poisons” (*véénéux*)—an outdated designation used in many Francophone countries.

In order to fulfil their obligations under international human rights law, governments should remove unnecessary barriers facing patients who need access to palliative care. The International Covenant on Economic, Social and Cultural Rights, to which Morocco is a party, requires that the government of Morocco act expeditiously to ensure access to palliative care and pain medicines.

Morocco has clearly identified palliative care as an important health issue. It has already eliminated a number of key barriers to providing this health service and has initiated steps to boost its availability, especially at the tertiary level. As a result, it is well positioned to take on the important task of ensuring palliative care is available to all Moroccans who need it.

But that will require the government to remove remaining barriers to the provision of palliative care and to significantly step up its efforts to ensure palliative care services become available

throughout the public healthcare system. In doing so, Morocco has the potential to be a leader in Francophone Africa, a region where palliative care is extremely limited.

Key Recommendations

To the Government of Morocco

- **Establish general palliative care centers at each of the five university hospitals.** This is an essential step in Morocco’s efforts to integrate palliative care into its healthcare system. Not only do these hospitals attend to all types of patients with chronic illnesses, they also play a key role in the academic and clinical training of healthcare workers and in conducting research, thus addressing three urgent needs identified in this report.
- **Establish palliative care centers at all regional oncology centers and the pediatric oncology hospital in Rabat.** Ensure that all currently operational regional cancer centers, as well as ones that are newly opened, have palliative care units. These centers can then serve as the basis for the further decentralization of palliative care. A palliative care unit at the pediatric oncology unit in Rabat could form the basis for developing pediatric palliative care and decentralizing it over time.
- **Integrate pain treatment and ensure the availability of oral opioid analgesics at secondary care facilities.** Ensure that all local, provincial, and regional hospitals have staff adequately trained in assessing and managing pain and that oral morphine is available. It should ensure that there are pharmacies near these hospitals that stock oral morphine or, alternatively, the hospital pharmacies should dispense it to outpatients.
- **Remove remaining structural barriers to palliative care.** In particular, develop a program of continuing medical education for active healthcare workers; ensure medical insurance covers medications for outpatients requiring palliative care; counter misunderstandings and fear around opioid analgesics; and increase the number of physicians with prescription privileges.

Methodology

This report is based on an assessment conducted between September 2014 and March 2015, including visits to Morocco in September 2014 and January 2015. Field investigation was conducted primarily in Casablanca and Rabat. Additional research was conducted in regional capitals and smaller cities in four northwestern regions. We also conducted extensive desk research regarding palliative care availability in various other parts of the country.

Over a total of five weeks in Morocco, three Human Rights Watch researchers conducted 85 interviews with a wide variety of stakeholders, including 24 people with cancer or their relatives; 35 healthcare workers, including oncologists, anesthesiologists, and palliative care doctors; 17 private pharmacists; and representatives of the WHO; the Ministry of Health; the Lalla Salma Foundation; Laprophan, a pharmaceutical company; national pharmaceutical associations; and The National Order of Doctors.

Interviews with patients and their relatives were conducted at a variety of hospitals. They were conducted in private whenever possible. Interviews were semi-structured and covered a range of topics related to palliative care and pain treatment. Before each interview, we informed interviewees of its purpose, the kinds of issues that would be covered, and asked whether they wanted to participate. We informed them that they could discontinue the interview at any time or decline to answer any specific questions, without consequence.

No incentives were offered or provided to persons interviewed. We have disguised the identities of all patients, relatives, and healthcare workers we interviewed in this report to protect their privacy, except when they specifically agreed that their real name could be used.

Most interviews were conducted in French or Arabic with the assistance of an interpreter. Some interviews were done in English.

Between October 2014 and January 2015, Human Rights Watch repeatedly sought permission from government officials in the Ministry of Health to conduct interviews with Ministry of Health officials, as well as healthcare providers, hospital administrators, and patients in government health facilities. Although the Health Ministry initially indicated that it would issue a written permission for us to conduct interviews in public hospitals, as

of June 2015, no such permission was issued. As a result, we were unable to interview all of the personnel whose views we sought.

In April 2015, Human Rights Watch presented a written memorandum with preliminary findings to the Ministry of Health along with a list of specific questions.

In June 2015, Human Rights Watch received a response from Dr. Abdelali Belghiti Alaoui, secretary general of the Ministry of Health. The response answered a number of our questions and raised issue with some of our preliminary findings and recommendations. The ministry's response emphasized Morocco's progress in expanding access to palliative care to date and stated a commitment to further steps. We have incorporated the ministry's response in the relevant sections of the report.

This report builds on previous research by Human Rights Watch on access to palliative care in Morocco, published in the 2011 report, *The Global State of Pain Treatment: Access to Palliative Care as a Human Right*.

All documents cited in the report are either publicly available or on file with Human Rights Watch.

I. Background

Importance of Palliative Care and Pain Relief

With life expectancy increasing worldwide, the prevalence of non-communicable diseases (NCDs) and chronic illnesses is rising rapidly.¹ NCDs, such as cancer, heart disease, diabetes, and respiratory illnesses, are by far the leading cause of mortality in the world, accounting for 63.5 percent of all deaths.² They and other chronic illnesses are often accompanied by pain and other distressing symptoms, such as breathlessness, nausea, anxiety, and depression (see Table 1).

Symptom	Cancer	COPD*	Chronic Heart Failure	Renal Disease	Dementia	AIDS	Parkinson's	Motor Neuron Disease	MS*
Pain	30-94%	21-77%	14-78%	11-83%	14-63%	30-98%	42-85%	52-76%	68%
Dyspnea	16-77%	56-98%	18-88%	11-82%	12-52%	43-62%	--**	81-88%	26%
Nausea	2-78%	4%	2-48%	8-52%	8%	41-57%	--	--	26%
Fatigue	23-100%	32-96%	42-82%	13-100%	22%	43-95%	42%	--	80%
Confusion	2-68%	14-33%	15-48%	35-70%	--	--	24%	24%	--
Constipation	4-64%	12-44%	12-42%	8-65%	40%	19-35%	24%	52-56%	46%
Diarrhea	1-25%	--	12%	8-36%	--	29-53%	--	--	--
Depression	4-80%	17-77%	6-59%	2-61%	46%	17-82%	15-50%	23%	15%
Anxiety	3-74%	23-53%	2-49%	7-52%	8-72%	13-76%	5-62%	19%	24%

*COPD: Chronic Obstructive Pulmonary Disease; MS: Multiple Sclerosis.

**Indicates that no data was available for this specific symptom.

Indicates an average of the lowest and highest available data on the prevalence of a specific symptom of 50 percent or greater.

Indicates an average of the lowest and highest available data on the prevalence of a specific symptom of 25 percent or greater.

¹ United Nations Department of Economic and Social Affairs (UNDESA) Population Division, "World Population Prospects: The 2012 Revision," 2013, p. 4, http://esa.un.org/wpp/Documentation/pdf/WPP2012_%20KEY%20FINDINGS.pdf (accessed May 15, 2015).

² UNDESA Population Division, "Changing Levels and Trends in Mortality: the Role of Patterns of Death by Cause," 2012, p. 7, <http://www.un.org/esa/population/publications/levelsandtrends/mortality/Changing%20levels%20and%20trends%20in%20mortality.pdf> (accessed March 31, 2015).

³ Katrien Moens, MSC, et al., "Are There Differences in the Prevalence of Palliative Care-Related Problems in People Living With Advanced Cancer and Eight Non-Cancer Conditions? A Systematic Review," *Journal of Pain and Symptom Management*, vol. 48, no. 4 (2014), pp. 667-669. Ranges reflect the minimum and maximum prevalence found in academic literature. Article includes important details on the academic literature from which the percentages are drawn.

Palliative care seeks to improve the quality of life of patients, both adults and children, facing life-limiting or advanced illness. Its purpose is not to cure a patient or extend his or her life, but rather to relieve pain and other physical and psychosocial problems. In the much-quoted words of Dame Cicely Saunders, the founder of the first modern hospice and a lifelong advocate for palliative care: palliative care is about “adding life to the days, not days to the life.” Although curative treatment may sometimes be available, palliative care seeks to reduce the burden and impact of these physical symptoms regardless of whether the underlying cause can be cured.

The World Health Organization (WHO) recognizes palliative care as an integral part of healthcare that should be available to those who need it.⁴ While palliative care is often associated with cancer, a much wider circle of patients can benefit from it, including patients in advanced stages of neurological disorders and cardiac, lung, liver, or renal disease.⁵ Indeed, the WHO and Worldwide Hospice and Palliative Care Alliance (WHPCA) estimate that over 65 percent of adults in need of palliative care have a chronic illnesses other than cancer.⁶

An important aspect of palliative care is addressing chronic, severe pain. Persistent pain has a profound impact on quality of life and can have physical, psychological, and social consequences. It can lead to reduced mobility and consequent loss of strength; compromise the immune system; and interfere with a person’s ability to eat, concentrate, sleep, or interact with others.⁷ The physical effect of chronic pain and the psychological strain it causes can even influence the course of disease: as the WHO notes in its cancer control guidelines, “pain can kill.”⁸ Social consequences include the inability to work; care for oneself, children, or other family members; participate in social activities; and find closure at the end of life.⁹

⁴ World Health Organization (WHO), “National Cancer Control Programmes: Policies and Managerial Guidelines, Second Edition,” 2002, pp. 86-87, <http://www.who.int/cancer/media/en/408.pdf> (accessed March 31, 2015).

⁵ WHO, “Strengthening of Palliative Care as a Component of Integrated Treatment Throughout the Life Course,” 2013, EB134/28, para. 7. http://apps.who.int/gb/ebwha/pdf_files/EB134/B134_28-en.pdf (accessed May 15, 2015).

⁶ WHO and Worldwide Hospice and Palliative Care Alliance (WHPCA), “Global Atlas of Palliative Care at the End of Life,” January 2014, p. 14, http://www.who.int/nmh/Global_Atlas_of_Palliative_Care.pdf (accessed May 15, 2015).

⁷ Frank Brennan, et al., “Pain Management: A Fundamental Human Right,” *Anesthesia & Analgesia*, vol. 105, no. 1 (2007), pp. 205-221.

⁸ WHO, “National Cancer Control Programmes,” p. 83, <http://www.who.int/cancer/media/en/408.pdf>.

⁹ Randall Daut, et al., “Development of the Wisconsin Brief Pain Questionnaire to Assess Pain in Cancer and Other Diseases,” *Pain*, vol. 17, no. 2 (1993), pp. 197-210.

According to the WHO, “Most, if not all, pain due to cancer *could* be relieved if we implemented *existing* medical knowledge and treatments” (original emphasis).¹⁰ The mainstay medication for the treatment of moderate to severe pain is morphine, an inexpensive opioid that is made of an extract of the poppy plant. Morphine is a controlled medication, meaning that its manufacture and distribution is strictly regulated both at the international and national levels.

Medical experts have recognized the importance of opioid pain relievers for decades. The 1961 Single Convention on Narcotic Drugs, the international treaty that governs the use of narcotic drugs, explicitly states that “the medical use of narcotic drugs continues to be indispensable for the relief of pain and suffering,”¹¹ and the WHO has recognized that strong opioids, such as morphine, are “absolutely necessary.”¹²

While pain is often a key symptom in people with life-limiting illnesses, palliative care is broader than just relief of physical pain. For example, many people with chronic illness experience shortness of breath—or dyspnea—a distressing symptom that makes the patient feel they can never get enough air.¹³ The physical and psychological effects of dyspnea can cause depression, anxiety, and insomnia.¹⁴ The psychological effects of dyspnea are particularly pronounced, as even mild alterations in breathing patterns may be “cognitively and emotionally interpreted as serious threats to health and life....”¹⁵ Treatment protocols, such as breathing techniques, oxygen, and relaxation, have been shown to provide significant relief for some patients with dyspnea.¹⁶ Increasingly, morphine has also been recommended to reduce the symptoms of dyspnea.¹⁷

¹⁰ WHO, “Achieving Balance in Opioid Control Policy: Guidelines for Assessment,” 2000, p. 1, http://whqlibdoc.who.int/hq/2000/who_edm_qsm_2000.4.pdf (accessed May 15, 2015).

¹¹ United Nations Economic and Social Council (ECOSOC), “Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol amending the Single Convention on Narcotic Drugs, 1961,” preamble, https://www.unodc.org/documents/commissions/CND/Int_Drug_Control_Conventions/Ebook/The_International_Drug_Control_Conventions_E.pdf (accessed March 31, 2015).

¹² *Ibid.*

¹³ A-L Jennings, et al., “A Systematic Review of the Use of Opioids in the Management of Dyspnoea,” *Thorax*, vol. 57 (2002), p. 939, <http://thorax.bmj.com/content/57/11/939.full.pdf+html> (accessed March 31, 2015).

¹⁴ Amy P Abernethy, et al., “Randomized, Double Blind, Placebo Controlled Crossover Trial of Sustained Release Morphine for the Management of Refractory Dyspnoea,” *BMJ*, vol. 327 (2003), p. 1, <http://www.bmj.com/content/327/7414/523.full.pdf+html> (accessed March 31, 2015).

¹⁵ James Hallenbeck, M.D., “Pathophysiologies of Dyspnea Explained: Why Might Opioids Relieve Dyspnea and Not Hasten Death?” *Journal of Palliative Medicine*, vol. 15, no. 8 (2012), p. 849.

¹⁶ American College of Chest Physicians, “Consensus Statement on the Management of Dyspnea in Patients with Advanced Lung and Heart Disease,” 2010, pp. 675-76, <http://journal.publications.chestnet.org/data/Journals/CHEST/22082/chest.09-1543.pdf> (accessed March 31, 2015); British Columbia Medical Association, et al., “Guidelines & Protocols, Palliative Care for

People with life-limiting illness and their relatives also frequently confront profound psychosocial and spiritual questions as they face life-threatening, incurable, and often debilitating illness. Anxiety and depression are common symptoms.¹⁸ Palliative care interventions like psychosocial counseling and spiritual support have been shown to considerably diminish the incidence and severity of such symptoms and to improve the quality of life of patients and their families.¹⁹

The WHO has urged countries, including those with limited resources, to make palliative care services available. The WHO recommends that countries prioritize implementing palliative care services both in medical institutions that deal with large numbers of patients requiring palliative care and in the community where it can be provided at low cost to people with limited access to medical facilities.²⁰

The WHO has observed that these measures cost very little but can have a significant effect.²¹ Indeed, as many countries face difficulty accommodating the increased demand for NCD services,²² some studies have found that offering palliative care leads to overall cost savings for health systems by reducing the pressure on medical systems.²³

In recent years, the World Bank and the WHO have urged countries to implement free universal health coverage to ensure that all people obtain the health services they need

the Patient with Incurable Cancer of Advanced Disease Part 2: Pain and Symptom Management Dyspnea,” 2011, pp. 1-3, http://www.bcguidelines.ca/guideline_palliative2.html (accessed March 31, 2015).

¹⁷ American College of Chest Physicians, “Consensus Statement on the Management of Dyspnea in Patients with Advanced Lung and Heart Disease,” pp. 675-76; Darcy D Marciniuk, et al., “Managing Dyspnea in Patients with Advanced Chronic Obstructive Pulmonary Disease: A Canadian Thoracic Society Clinical Practice Guideline,” *Canadian Respiratory Journal*, vol. 18 (2011), p. 4, http://www.respiratoryguidelines.ca/sites/all/files/2011_CTS_guideline_COPD_dyspnea.pdf (accessed May 15, 2015); Jennings, “A Systematic Review of the Use of Opioids in the Management of Dyspnoea,” *Thorax*, p. 941; Abernethy, “Randomized, Double Blind, Placebo Controlled Crossover Trial of Sustained Release Morphine for the Management of Refractory Dyspnoea,” *BMJ*, p. 3.

¹⁸ Joao Paulo Solano, et al., “A Comparison of Symptom Prevalence in Far Advanced Cancer, AIDS, Heart Disease, Chronic Obstructive Pulmonary Disease and Renal Disease,” *Journal of Pain and Symptom Management*, vol. 31, no. 1 (2006).

¹⁹ See, for example, WHO, “National Cancer Control Programmes,” pp. 83-91, <http://www.who.int/cancer/media/en/408.pdf>.

²⁰ WHO, “Strengthening of Palliative Care as a Component of Integrated Treatment Throughout the Life Course,” paras. 19-20, http://apps.who.int/gb/ebwha/pdf_files/EB134/B134_28-en.pdf; WHO, “National Cancer control Programme,” pp. 91-92, <http://www.who.int/cancer/media/en/408.pdf>.

²¹ WHO, “Cancer Pain Relief, With a Guide to Opioid Availability, Second Edition,” 1996, p. 43, <http://whqlibdoc.who.int/publications/9241544821.pdf> (accessed May 14, 2015).

²² Ministry of Health, “Sectoral Strategy for Health 2012-2016” (“Strategie Sectorielle de Santé 2012-2016”), 2012, p. 17, <http://www.sante.gov.ma/Docs/Documents/secteur%20sant%C3%A9.pdf> (accessed July 29, 2015).

²³ Rolfe Sean Morrison, et al., “Cost Savings Associated with US Hospital Palliative Care Consultation Programs,” *Arch Intern Med*, vol. 168 (2008), <http://archinte.jamanetwork.com/article.aspx?articleid=414449> (accessed June 27, 2014).

without suffering financial hardship.²⁴ Palliative care is one of the basic health services that the WHO says should be available under universal health coverage.²⁵

Global and Regional Availability of Palliative Care

Despite the importance of this essential healthcare service, access to palliative care has lagged behind the development of other health services due to well-documented barriers in the areas of healthcare policy, healthcare education, and medication availability.²⁶ Indeed, a joint report by the WHO and WHPCA states that 98 countries have no known palliative care services.²⁷

According to the International Narcotics Control Board (INCB)—the body charged with monitoring the 1961 Single Convention on Narcotic Drugs— “approximately 5.5 billion people, or three quarters of the world’s population ... have inadequate access to treatment for moderate to severe pain....”²⁸ Due to limited access to essential medications, the WHO estimates that tens of millions of people around the world, including around 5.5 million end-stage cancer patients and one million people with AIDS, suffer from moderate to severe pain each year without treatment.²⁹

Palliative care development is particularly weak in Francophone Africa. A 2012 study, for example, found that 16 out of 22 Francophone African countries do not have any healthcare providers that offer palliative care. In contrast, the same study found that nearly all Anglophone African countries had at least some palliative care services (see Table II).

²⁴ For the definition of universal health coverage, see:

http://www.who.int/health_financing/universal_coverage_definition/en/ (accessed June 3, 2014); World Bank, “Universal Health Coverage Study Series,” <http://www.worldbank.org/en/topic/health/publication/universal-health-coverage-study-series> (accessed March 11, 2015).

²⁵ WHO, “Strengthening of Palliative Care as a Component of Integrated Treatment Throughout the Life Course,” para 20(ii), http://apps.who.int/gb/ebwha/pdf_files/EB134/B134_28-en.pdf.

²⁶ See, for example, WHO and WHPCA, “Global Atlas of Palliative Care at the End of Life,” pp. 27-29, http://www.who.int/nmh/Global_Atlas_of_Palliative_Care.pdf.

²⁷ *Ibid.*, p. 36. Findings are based on a study published in the *Journal of Pain and Symptom Management*. Thomas Lynch, PhD, et al., “Mapping Levels of palliative Care Development: A Global Update,” *Journal of Pain and Symptom Management*, vol. 45, no. 6 (2013).

²⁸ INCB, “Report 2014,” 2015, p. 3.

https://www.incb.org/documents/Publications/AnnualReports/AR2014/English/AR_2014.pdf (accessed March 23, 2015).

²⁹ WHO Briefing Note, “Access to Controlled Medications Programme,” 2012,

http://www.who.int/medicines/areas/quality_safety/ACMP_BrNote_Genrl_EN_Apr2012.pdf?ua=1 (accessed March 31, 2015).

Francophone Africa also has some of the lowest rates of morphine consumption globally. The INCB classifies each country in the region, with the exception of Tunisia, as having “very inadequate” opioid availability.³⁰ More than two-thirds of the countries in the region for which data is available use so little morphine that it is not even sufficient to treat 5 percent of people dying in pain from cancer and AIDS (see Table III). In 2013, Human Rights Watch documented the devastating impact that lack of palliative care services had on patients and their families in Senegal, where many patients said they felt they had been abandoned in their agony.³¹

³⁰ INCB, “Availability of Opioids for Pain Management (2010-2012 average),” 2012, https://www.incb.org/documents/Narcotic-Drugs/Availability/total_2010_2012_final.pdf (accessed May 14, 2015) (Tunisia is classified as having an “inadequate” supply of opioids).

³¹ Human Rights Watch Report, “Abandoned in Agony: Cancer and the Struggle for Pain Treatment in Senegal,” (New York: Human Rights Watch, November 2013), http://www.hrw.org/sites/default/files/reports/senegal1013_forinsert_ForUpload.pdf (May 14, 2015).

Table II: Comparison of Palliative Care Development in Francophone and Anglophone Africa³²

Francophone Africa ³³		Anglophone Africa	
WHPCA/WHO Level of Palliative Care Development		WHPCA/WHO Level of Palliative Care Development	
Benin			Liberia
Burkina Faso			Mauritius
Burundi			Seychelles
Central African Republic			Botswana
Chad			The Gambia
Comoros			Ghana
Djibouti			Lesotho
Gabon			Namibia
Guinea			Nigeria
Mauritania			Rwanda
Niger			Sierra Leone
Senegal			Sudan*
Togo			Swaziland
Algeria			Kenya
Democratic Republic of the Congo			Malawi
Madagascar			South Africa
Cameroon			Tanzania
Congo			Zambia
Mali			Zimbabwe
Morocco			Uganda
Tunisia			
Côte d'Ivoire			

*Data was collected in 2011, prior to South Sudan's independence in September of that year.

- No known palliative care provision or initiatives to develop it.
- No known palliative care provision but evidence of some initiatives to develop it.
- A small number of palliative care services operational.
- Multiple palliative care services operational but not integrated into the healthcare system.
- Palliative care is partially integrated into the healthcare system.
- Comprehensive provision of palliative care throughout the country.

³² WHO and WHPCA, "Global Atlas of Palliative Care at the End of Life," p. 36, http://www.who.int/nmh/Global_Atlas_of_Palliative_Care.pdf. Thomas Lynch, PhD, et al., "Mapping Levels of Palliative Care Development: A Global Update," *Journal of Pain and Symptom Management*, vol. 45, no. 6, June 2013. The study collected data from numerous sources, including academic literature, palliative care directories, statistics on opioid availability, in-country "key experts", and regional palliative care associations. Countries were grouped into six categories, represented above.

³³ To categorize countries as Francophone or Anglophone, we looked at the prevalence of spoken French or English within each country. In countries where both languages are commonly spoken, we considered the following factors in making our determination: language officially recognized by the government; language used in government affairs; language used in educational settings; and colonial history. The level of palliative care development and/or morphine consumption within a given country was not a consideration in our determination.

Map Comparing Francophone and Anglophone Africa










Table III: Opioid Consumption Data for Francophone Africa ³⁴			
Country	Estimated Annual Cancer and AIDS Deaths with Moderate to Severe Pain (2012)	Estimated Number of Terminal Cancer and AIDS Patients who:	
		Are not Receiving Adequate Pain Treatment (Minimum Number)	Could be treated with all Strong Opioids Consumed (percentage)
Burundi	6,933	--	--
Central African Republic	7,237	--	--
Comoros	329	--	--
Congo	3,796	--	--
Djibouti	848	--	--
Guinea	5,931	--	--
Mauritania	1,576	--	--
Niger	5,419	--	--
Burkina Faso	7,722	7,681	<1%
Côte d'Ivoire	22,939	22,827	<1%
Gabon	1,645	1,637	<1%
Chad	10,787	10,634	1%
Democratic Republic of the Congo	40,626	40,122	1%
Mali	7,991	7,915	1%
Togo	5,808	5,732	1%
Cameroon	25,049	24,497	2%
Madagascar	13,473	12,269	2%
Senegal	4,832	4,757	2%
Benin	4,568	4,402	4%
Morocco	18,838	15,163	20%
Algeria	17,860	13,971	22%
Tunisia	5,921	0	124%

-  Country did not report opioid consumption to the INCB during 2010-2012.
-  Consumption of less than or equal to 2 percent of that needed to treat all cancer and HIV/AIDS patients with pain.
-  Consumption of between 2.1 and 5 percent of that needed to treat all cancer and HIV/AIDS patients with pain.
-  Consumption of between 5.1 and 25 percent of that needed to treat all cancer and HIV/AIDS patients with pain.
-  Consumption of between 25.1 and 99 percent of that needed to treat all cancer and HIV/AIDS patients with pain.
-  Consumption of equal to or greater than 100 percent of that needed to treat all cancer and HIV/AIDS patients with pain.

³⁴ American Cancer Society, "Treat the Pain, Country Reports," http://www.treatthepain.org/country_reports.html (accessed March 3, 2015). Methodology: Research suggest that approximately 80 percent of terminal cancer patients and 50 percent of terminal HIV/AIDS patients will suffer from moderate to severe pain. Kathleen M. Foley, et al., "Pain Control for People with Cancer and AIDS," in *Disease Control Priorities in Developing Countries*, ed. Dean T Jamison, et al., vol. 2 (Washington (DC): World Bank, 2006). Foley and others estimate that the average terminal cancer or AIDS patient who suffers from moderate to severe pain will need 60 to 75mg of morphine per day for an average of about 90 days. Using the average of the INCB's three most recent years of opioid consumption data (2010-2012) and cancer and AIDS mortality rates, the American Cancer Society has calculated the percentage of individuals with late-stage cancer and AIDS who could have been treated with opioids. This is a very conservative estimate of the actual need for pain treatment. These calculations focus on patients with terminal cancer and AIDS who die each year without access to adequate pain medication. Given that morphine is also used to treat various other illnesses and to relieve post-surgical pain and that patients with a variety of other illnesses also suffer from moderate to severe pain that requires treatment with opioids, the actual unmet need for pain relief is likely far greater. Our calculations exclude methadone, as methadone is most commonly used in opioid dependence treatment.

Background on Morocco's Healthcare System

Morocco's healthcare system is comprised of a public sector, a private non-profit sector, and a private for-profit sector.³⁵

The public sector makes up the majority of the overall healthcare system, although the private sector is growing rapidly and now represents 32 percent of the healthcare system.³⁶ The public sector includes specialty hospitals and university hospitals (*centres hospitaliers universitaires*); regional, provincial, and local hospitals; and basic healthcare centers.³⁷ Although private sector options are available and offer higher quality care compared to their public counterparts, the services are much more costly, particularly for the approximately 21 million Moroccans who do not have health insurance or whose insurance only covers care at public health facilities.³⁸

Morocco's public healthcare system consists of three levels of care (see Chart I).³⁹ University hospitals and specialty hospitals, all tertiary care facilities, are the most sophisticated healthcare facilities with generally well-stocked pharmacies and a broad range of specialists, advanced medical equipment, and treatment options. These facilities are located only in major cities. Many smaller cities have regional, provincial, or local hospitals. These secondary care facilities have inpatient and outpatient facilities available but may only have a limited number of key specialists. Local hospitals, for example, have essential medical disciplines, such as obstetrics, general medicine, and general surgery, but no specialist in ophthalmology, gastroenterology, or cardiology.⁴⁰ Finally, at health

³⁵ Hassan Semlali, "The Moroccan Practice Case Study: Positive Practice Environments in Morocco," 2010, p. 16, http://www.who.int/workforcealliance/knowledge/PPE_Morocco_CaseStudy.pdf (accessed March 31, 2015).

³⁶ Ministry of Health, "Sectoral Strategy for Health 2012-2016" ("Strategie Sectorielle de Santé 2012-2016"), p. 14, <http://www.sante.gov.ma/Docs/Documents/secteur%20sant%C3%A9.pdf>.


³⁷ Ibid., pp. 16-17; Décret relatif à l'organisation hospitalière, No. 2-06-656, art. 7, 2007, http://www.sante.gov.ma/Reglementation/Organisation_Minist/Documents/ORGANISATION%20HOSPITALIERE.pdf (accessed July 29, 2015).

³⁸ Hassan Semlali, "The Moroccan Practice Case Study: Positive Practice Environments in Morocco," 2010, p. 16; Human Rights Watch interview with private general oncological surgeon (name withheld), January 14, 2014.

³⁹ Ministry of Health and Lalla Salma Foundation, "National Cancer Prevention and Control Plan" ("Plan Nationale de Prévention et de Contrôle Du Cancer") pp. 29-30, http://www.contrelecancer.ma/site_media/uploaded_files/PNPCC_-_Axes_strategiques_et_mesures_2010-2019.pdf (accessed March 31, 2015).

⁴⁰ Décret relatif à l'organisation hospitalière, no. 2-06-656, art. 7, 2007, http://www.sante.gov.ma/Reglementation/Organisation_Minist/Documents/ORGANISATION%20HOSPITALIERE.pdf. Local, provincial, and regional hospitals have a hierarchical structure themselves, growing in sophistication and reach as one moves up the chain. In addition to the services provided at local hospitals, provincial hospitals should have additional specialists, such as psychiatrists, gastroenterologists, and cardiologists. Regional hospitals should have additional specialists, such as plastic and reconstructive surgeons, urologist, and neurosurgeons.

centers, available in small towns, there may only be a general care physician or a traveling nurse or midwife who offers basic care.



The ratio of healthcare workers and facilities to the population is comparatively low in Morocco. According to the WHO's most recent data, Morocco had a substantially lower number of hospital beds, physicians, and nurses and midwives per citizen than its North African neighbors.⁴¹ In 2005-2012, for example, the WHO reports that Morocco had approximately 6 physicians for every 10,000 individuals, compared to 12 physicians per 10,000 in Algeria and Tunisia, 19 in Libya, and 28 in Egypt.⁴²

⁴¹ WHO, "World Health Statistics: 2013," 2013, pp. 120-127, http://apps.who.int/iris/bitstream/10665/81965/1/9789241564588_eng.pdf?ua=1 (accessed March 23, 2015); WHO, "World Health Statistics: 2010," 2010, p. 117, http://www.who.int/entity/whosis/whostat/EN_WHS10_Full.pdf?ua=1 (accessed March 23, 2015). Hospital bed rates in Algeria are based on the 2010 report, as no statistics are available for 2013.

⁴² WHO, "World Health Statistics: 2013," 2013, pp. 120-127.

As of 2012, Morocco’s per capita health expenditure was US\$190 per person and its total health expenditure was 6 percent of GDP.⁴³ Although Morocco’s health expenditure is relatively similar to that of its North African neighbors, a significantly smaller proportion comes from public funds. In 2012, for example, Morocco’s state budget accounted for approximately 34 percent of total health expenditures, compared to 59 percent in Tunisia, 77 percent in Libya, and 84 percent in Algeria.⁴⁴

Since 2005, the Moroccan government has sought to broaden health insurance coverage for its population. Prior to the reforms initiated that year, formal health insurance coverage in Morocco was voluntary and only 17 percent of the population—more than two-thirds of them government employees covered by a public insurance scheme—was insured.⁴⁵

A small percentage of the population was covered through private insurance, while the vast majority of the population did not have health insurance. Low-income citizens could qualify for a “certificate of indigence” (*certificat d’indigence*) from their local government, which provided them with either free or low cost healthcare from public facilities. Those who did not qualify for this certificate could receive healthcare in public facilities at a subsidized rate.⁴⁶

Since 2005, the government has instituted two major health insurance reforms. First, it introduced a compulsory health insurance program known as Assurance Maladie Obligatoire (AMO) that covers both salaried public and private sector employees.⁴⁷ Premiums for AMO are roughly split by employees and employers. AMO covers a fixed percentage—ranging from roughly 70 to 90 percent—of the cost of a number of medical

⁴³ Global health expenditure data can be found here: apps.who.int/nha/database/ViewData/Indicators/en (accessed July 29, 2015).

⁴⁴ Ibid.

⁴⁵ Driss Zine-Eddine El-Idrissi, et al. “Constraints and Obstacles to Social Health Protection in the Maghreb: The Case of Algeria and Morocco,” *Bulletin of the World Health Organization*, vol. 86, issue 11 (2008), [who.int/bulletin/volumes/86/11/08-053736/en/](http://www.who.int/bulletin/volumes/86/11/08-053736/en/) (accessed November 6, 2014); Jennifer Prah Ruger and Daniel Kress, “Health Financing and Insurance Reform in Morocco,” *Health Affairs*, vol. 26, no. 4, (2007) p. 1010, <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898512/pdf/nihms-216679.pdf> (accessed July 29, 2015).

⁴⁶ Ruger and Kress, “Health Financing and Insurance Reform in Morocco,” *Health Affairs*, pp. 1010-1011.

⁴⁷ Ibid., p. 1012; El-Idrissi, et al. “Constraints and Obstacles to Social Health Protection in the Maghreb: The Case of Algeria and Morocco,” 2008.

interventions and medicines.⁴⁸ By 2012, 7.6 million Moroccans were covered by AMO (approximately 23 percent of the population).⁴⁹

In 2011, the government launched another major reform establishing the Regime d'Assistance Médicale (RAMED), a public insurance scheme that provides coverage to low-income populations. RAMED largely replaces the “certificate of indigence” with a more formal system for providing free or reduced-cost healthcare services to those living in poverty. Candidates for the program are divided into two categories—urban and rural—and qualify based on factors such as household income or living conditions. Urban residents, for example, can receive free healthcare services if, among other qualifications, they make less than 3,767 MAD (US\$423) per year.⁵⁰

In theory, people who qualify for RAMED can receive essential healthcare services in public hospitals and public health centers around the country, but the facilities that they have access to may not always provide them with the care and medicines that they need.⁵¹ Indeed, public health facilities often suffer from underfunding,⁵² poor quality of reception and care,⁵³ and are difficult to access for rural Moroccans.⁵⁴ Similarly, RAMED only covers medications dispensed from public pharmacies. With few exceptions, public pharmacies

⁴⁸ Details on the percentage of each service covered by AMO can be found here:

http://www.anam.ma/anam.php?id_espace=5&id_srub=12 (accessed July 29, 2015). The medicines and services covered can be found here: http://www.anam.ma/anam.php?id_espace=5&id_srub=13 (accessed July 29, 2015).

⁴⁹ Agence Nationale de l'Assurance Maladie, “Feuille De Route: 2014-2018,” p. 12, <http://www.anam.ma/upload/document/feuillederoute.pdf> (accessed April 1, 2015).

⁵⁰ Urban residents must also have a total socio-economic conditions score less than or equal to 11. Fixant les variables liées aux conditions de vie, les coefficients de pondération du revenu déclaré, les indices de calcul du score patrimonial, les indices de calcul des scores des conditions socioéconomiques ainsi que la méthode de calcul desdits scores pour le bénéficiaire du régime d'assistance médicale, no. 836-08 of 2008, art. 4, http://www.ramed.ma/SInformer/DocTelecharger/arrete_%20criteres_deligibilit-FR.pdf (accessed May 14, 2015). Urban residents who make between 3,767 and 5,650 MAD (US\$423-US\$634) a year pay an annual contribution of 120 MAD (US\$13) per person, with a 600 MAD (US \$67) family cap. Portant application des dispositions du livre I de la loi n° 65-0 relatives au régime d'assistance médicale, no. 2-08-77 of 2008, art. 25, https://www.ramed.ma/SInformer/DocTelecharger/Decret_2-08-177.pdf (accessed May 14, 2015). Rural residents, in contrast, must prove that they have a “heritage score” (*le score patrimonial*) less than or equal to 28 and a socio-economic score less than or equal to 6. Details on how to calculate the two scores can be found here: Law no. 836-08, arts. 5-6.

⁵¹ A list of medicines and health services covered under RAMED can be found here:

<https://www.ramed.ma/SInformer/Pages/PanierSoins.html> (accessed March 31, 2015).

⁵² WHO, “Country Cooperation Strategy for WHO and Morocco: 2008-2013,” 2009, p. 14.

http://www.who.int/countryfocus/cooperation_strategy/ccs_mar_en.pdf (accessed May 15, 2015).

⁵³ Ruger and Kress, “Health Financing and Insurance Reform in Morocco,” *Health Affairs*, p. 1010; Semlali, “The Moroccan Practice Case Study,” 2010, p. 22.

⁵⁴ Semlali, “The Moroccan Practice Case Study,” 2010, p. 17.

only supply medications to patients during hospitalization.⁵⁵ Thus, RAMED’s coverage only extends to “drugs and pharmaceuticals administered during [inpatient] treatment.”⁵⁶ Outpatients have to fill and pay for their prescriptions at private pharmacies.

As of 2013, 5.6 million Moroccans were covered by RAMED—approximately 17 percent of the population—bringing the total of medically covered Moroccans to just over 50 percent of the population.⁵⁷ The other nearly 50 percent of the Moroccan population is uninsured. In particular, insuring those who are eligible but not receiving RAMED (approximately 2.5 million people) and those working within the informal economy (approximately 10 million people) remain large obstacles to achieving universal health coverage.⁵⁸

In the coming years, Morocco plans to continue efforts to expand health coverage to larger segments of the population, including those noted above.⁵⁹ Notably, the government sought and received a combined US\$166 million in financing from the African Development Bank and European Union for continued health insurance reform efforts.⁶⁰

⁵⁵ There is an exception to this general rule for outpatients who receive care at regional oncology centers. These patients can benefit from a joint program of the Lalla Salma Foundation and the Ministry of Health, called the ACCESS program, which is designed to improve access to cancer medications for low-income patients. They can fill their prescriptions at the hospital pharmacies of the oncology centers free of charge.

⁵⁶ A list of medicines and health services covered under RAMED can be found here: <https://www.ramed.ma/SInformer/Pages/PanierSoins.html> (accessed March 31, 2015).

⁵⁷ Agence Nationale de l’Assurance Maladie, “Feuille De Route: 2014-2018,” p. 12, <http://www.anam.ma/upload/document/feuillederoute.pdf> (accessed April 1, 2015). Approximately 4 million Moroccans are covered by smaller schemes or private insurance.

⁵⁸ *Ibid.*; WHO, “Country Cooperation Strategy for WHO and Morocco,” p. 15.

⁵⁹ African Development Bank, “Medical Coverage Reform Support Program (PARCOUM III),” 2013, http://www.afdb.org/fileadmin/uploads/afdb/Documents/Project-and-Operations/Morocco_-_Medical_Coverage_Reform_Support_Programme%E2%80%933_Phase_3__PARCOUM_III_-_Appraisal_Report.pdf (accessed April 1, 2015). In 2007, Morocco introduced the Inaya scheme, which aimed to provide health insurance to self-employed workers and freelance professionals. While the government ultimately hopes to make this scheme compulsory for 10 million Moroccans (one-third of the population), the program has so far not achieved significant coverage. Kingdom of Morocco, “Advanced Status Success Program” (“Reussir le statut avance”), 2011, pp. 6-7, <http://www.bmwi.de/Dateien/BMWi/PDF/Twinning/fiche-de-jumelage-programme-reussir-le-statut-avance-accompagner-la-mise-en-place-de-observation-et-le-suivi-des-indicateurs-de-protection-sociale,property=pdf,bereich=bmwi2012,sprache=de,rwb=true.pdf> (accessed May 15, 2015).

⁶⁰ Information on the African Development Bank’s contribution can be found here: <http://www.afdb.org/en/news-and-events/article/afdb-approves-eur15-million-for-inclusive-and-universal-health-coverage-in-morocco-12712/> (accessed July 29, 2015). Information on the European Union’s contribution can be found here: <http://www.maroc.ma/en/news/morocco-eu-sign-eu-50-million-financing-agreement-government-medical-coverage-reform-policy> (accessed July 29, 2015).

History of Palliative Care in Morocco

In the early 1990s, palliative care and pain treatment were virtually non-existent in Morocco.⁶¹ In 1994, Dr. Mati Nejmi, then chief of anesthesiology at the National Oncology Institute, recognized the urgent need for this health service and engaged Morocco's health policy makers and international groups in an effort to introduce palliative care in Morocco. Over the following years, this work achieved a number of significant milestones, including:

- Introducing oral morphine for the first time in Morocco (1995);
- Opening the Moroccan Society of Pain and Palliative Care (1996);
- Constructing the first palliative care unit in Morocco, adjoining the National Oncology Institute in Rabat (2005); and
- Developing the Sectoral Health Strategy (SHS) (2012) as well as its National Cancer Prevention and Control Plan (NCPCP) (2010), which include specific palliative care goals.⁶²

These improvements make clear that Morocco is well positioned to take on the important and necessary task of ensuring palliative care and pain treatment is available to all Moroccans who need it. In doing so, Morocco has the potential to be a regional leader in Francophone Africa, a region where palliative care is extremely limited.

⁶¹ The Pain and Policy Studies Group at the University of Wisconsin, a collaborating center of the WHO, has a graph of opioid consumption in Morocco over the years, which can be found here: http://www.painpolicy.wisc.edu/sites/www.painpolicy.wisc.edu/files/country_files/morphine_equivalence/morocco_mepdf (accessed July 29, 2015).

⁶² Mati Nejmi, M.D. and Leyla Hessissen, M.D., "Moroccan Experience," in *Palliative Care to the Cancer Patient: The Middle East as a Model for Emerging Countries*, ed. Michael Silberman (New York: Nova Publishers, 2014), pp. 145-46.

II. Palliative Care in Morocco and Patients' Experiences

Availability of Palliative Care in Morocco

Like many low and middle income countries, Morocco is currently experiencing an epidemiological transition with a decreasing prevalence of infectious diseases and an increased burden of NCDs and other chronic illnesses. In 2013, the WHO estimated that NCDs were responsible for 75 percent of deaths in the country.⁶³ As a result, more Moroccans than ever develop chronic conditions that are accompanied by pain and other symptoms that, if left untreated, can seriously undermine their quality of life.

And the burden of chronic illness is likely to rise. The percentage of people over 65, the segment of the population most affected by these illnesses, is expected to nearly double over the next 15 years.⁶⁴ In that same period, the incidence of cancer is expected to nearly triple.⁶⁵ As Morocco's health strategy puts it, "this will lead to a progressive increase in demand for major hospital care to provide treatment for chronic and degenerative diseases."⁶⁶ This transition has resulted in a significant and sustained increase in the need for palliative care.⁶⁷

Based on WHO estimates for palliative care needs in the Middle East region, around 62,000 Moroccans, including 6,000 children, require palliative care each year.⁶⁸ Tens of

⁶³ WHO, "Morocco-Noncommunicable Diseases (NCD) Country Profiles," 2014, http://www.who.int/nmh/countries/mar_en.pdf?ua=1 (accessed November 12, 2014). In 2013, according to the WHO, 70,040 individuals died due to cardiovascular disease in Morocco, 24,720 due to diabetes, 22,798 due to cancer, 8,240 due to chronic obstructive pulmonary disease, and 1,200 due to AIDS. Ministry of Health and Lalla Salma Foundation, "National Cancer Prevention and Control Plan" ("Plan Nationale de Prévention et de Contrôle Du Cancer"), p. 4 (estimates that NCDs account for 56 percent of all deaths in the country).

⁶⁴ UN demographic projection data can be found here: http://esa.un.org/wpp/unpp/panel_indicators.htm/. Ministry of Health, "Sectoral Strategy for Health 2012-2016" ("Strategie Sectorielle de Santé 2012-2016"), p. 10, <http://www.sante.gov.ma/Docs/Documents/secteur%20sant%C3%A9.pdf>.

⁶⁵ Ministry of Health and Lalla Salma Foundation, "National Cancer Prevention and Control Plan" ("Plan Nationale de Prévention et de Contrôle Du Cancer") p. 1, http://www.contrelecancer.ma/site_media/uploaded_files/PNPCC_-_Axes_strategiques_et_mesures_2010-2019.pdf.

⁶⁶ Ministry of Health, "Sectoral Strategy for Health 2012-2016" ("Strategie Sectorielle de Santé 2012-2016"), p. 11, <http://www.sante.gov.ma/Docs/Documents/secteur%20sant%C3%A9.pdf>.

⁶⁷ *Ibid.*, pp. 66, 69-70.

⁶⁸ The figure was calculated by multiplying the population of adults and children in Morocco by the estimated percentage of adults and children who will need palliative care within the Eastern Mediterranean (the WHO region that encompasses Morocco). WHO and WHPCA, "Global Atlas of Palliative Care at the End of Life," January 2014, pp. 98-99, http://www.who.int/nmh/Global_Atlas_of_Palliative_Care.pdf/. Population figures can be found here: <https://www.cia.gov/library/publications/the-world-factbook/geos/mo.html> (accessed July 29, 2015).

thousands of them will experience significant pain and may need treatment with opioid analgesics, such as morphine. Advanced cancer and AIDS alone cause moderate to severe pain in nearly 19,000 Moroccans annually.⁶⁹

Morocco's healthcare system currently does not have nearly the palliative care capacity to attend to all these patients. Our research identified two palliative care units within Morocco's public healthcare system, in Casablanca and Rabat. Each of these units is based in a tertiary-level cancer hospital and attends only to people with cancer (see Map I below).

While the WHO recommends that countries integrate palliative care at all levels of care, including in the community, our research did not find any palliative care providers at secondary levels of care. Indeed, interviews with medical personnel at eight secondary care facilities in eight different cities and towns, some as far as 150kms from the nearest tertiary care facility, revealed that none were offering palliative care or had oral morphine.


Our research also revealed that few private facilities offer palliative care.⁷⁰ In 2013, Dr. Mati Nejmi, former head of anesthesiology at the National Oncology Institute, opened the first private palliative care practice in the country in Casablanca.⁷¹ This means that there are large parts of Morocco—especially the south and the northeast—without any palliative care providers at all.

Although some healthcare providers have integrated palliative care interventions into their general practice, particularly tertiary level hospitals, Human Rights Watch believes that to be the exception, as most facilities simply do not have staff trained in palliative care or access to key palliative care medications, such as morphine.

⁶⁹ There were an estimated 22,798 Cancer deaths in Morocco in 2012, which can be found here: <http://globocan.iarc.fr/ia/World/atlas.html> (accessed November 12, 2014). According to the WHO there were an estimated 1,200 deaths due to HIV/AIDS, which can be found here: <http://apps.who.int/gho/data/view.main.22600?lang=en> (accessed July 29, 2015). Research suggest that approximately 80 percent of terminal cancer patients and 50 percent of terminal HIV/AIDS patients will suffer from moderate to severe pain. Foley, "Pain Control for People with Cancer and AIDS." Foley and others estimate that the average terminal cancer or AIDS patient who suffers from moderate to severe pain will need 60 to 75mg of morphine per day for an average of about 90 days. From this information, it is estimated that a minimum of 18,838 Moroccans are in need of pain treatment annually.

⁷⁰ Human Rights Watch interview with Dr. Mati Nejmi, former chief of anesthesiology at the National Oncology Institute in Rabat, Rabat, September 29, 2014.

⁷¹ Youssef Sourgo, "Creation of the First Unit for Palliative Care in a Private Clinic in Casablanca," *Morocco World News*, June 5, 2013, <http://www.morocroworldnews.com/2013/06/93462/creation-of-the-first-unit-for-palliative-care-in-a-private-clinic-in-casablanca/> (accessed March 21, 2015).




Data on the use of opioid analgesics suggests that there is a major gap in the treatment of moderate to severe pain in Morocco. The latest available data indicates that Morocco consumes an annual amount of morphine sufficient to treat approximately 3,700 patients with terminal cancer or AIDS per year—around 20 percent of those who need it.⁷² This estimate does not take into account the morphine needs of people with pain due to illnesses such as heart and lung disease or diabetes, even though it is a common symptom of each of these conditions. Since morphine is also used to treat pain caused by trauma and surgery, a considerable proportion of the morphine that Morocco consumes is not actually used in palliative care.

Despite this major gap, Morocco has made considerable progress in increasing morphine availability. Consumption has consistently increased since 1995, when morphine was first

⁷² See footnote 69. Treat the Pain, “Morocco—Treat the Pain: A Country Snapshot,” 2014, <http://www.treatthepain.org/Assets/CountryReports/Morocco.pdf> (accessed May 15, 2015). Our calculations exclude methadone, as methadone is exclusively used in opioid dependence treatment in Morocco.

introduced in Morocco (see Graph I below). Significantly, between 2012 and 2013, Morocco nearly doubled its morphine consumption. However, using INCB classification, Morocco’s 2013 morphine consumption is still considered “very inadequate.”⁷³

CONSUMPTION OF MORPHINE IN MOROCCO



Sources: International Narcotics Control Board; World Health Organization population data; 2013 morphine consumption data obtained from the Ministry of Health; Pain & Policy Studies Group, University of Wisconsin/WHO Collaborating Center, 2015.

⁷³ Explanation of how the INCB determines the adequacy of morphine consumption can be found here: <https://www.incb.org/incb/en/narcotic-drugs/Availability/availability.html> (accessed June 26, 2015).

THE FATE OF PATIENTS WITH NON-ONCOLOGICAL DISEASE

While patients with advanced cancer have very limited access to palliative care in Morocco, those with advanced non-oncological illnesses have almost none. Yet, the WHO and WHPCA estimate that over 70 percent of adults in need of palliative care from the WHO's Eastern Mediterranean region have a chronic illness other than cancer.⁷⁴ In other words, around 40,000 adults in Morocco require palliative care each year for conditions other than cancer.

The WHO has identified the following non-oncological diseases as conditions in which palliative care may be required: cardiovascular diseases, chronic obstructive pulmonary diseases, kidney failure, chronic liver disease, multiple sclerosis, Parkinson's disease, rheumatoid arthritis, neurological diseases, Alzheimer's disease and other dementias, and congenital anomalies and infectious diseases such as HIV/AIDS and drug-resistant tuberculosis.⁷⁵

As Table I (see page 10) demonstrates, people with these conditions often face multiple symptoms that undermine their quality of life. For example, up to 78 percent of people with end-stage chronic heart failure, Morocco's number one killer, experience pain; up to 88 percent experience breathlessness; up to 48 percent experience nausea; and up to 59 percent experience depression.⁷⁶

Experience of People in Need of Pain Treatment

Over the course of our research, we collected testimony from two dozen patients and their families about the challenges they faced while accessing palliative care. While a few patients reported having access to comprehensive palliative care—mostly those from Rabat and Casablanca—most had limited access or accessed it only with difficulty, often with long delays and after significant suffering from pain and other symptoms.

Yet, even they were the fortunate ones as they ultimately accessed palliative care. With opioids reaching a small fraction of those who need it, many more spend their last weeks and months without access to adequate care and often die under excruciating circumstances.

⁷⁴ WHO and WHPCA, "Global Atlas of Palliative Care at the End of Life," p. 16,

http://www.who.int/nmh/Global_Atlas_of_Palliative_Care.pdf.

⁷⁵ WHO, "Strengthening of Palliative Care as a Component of Integrated Treatment Throughout the Life Course," para. 7,

http://apps.who.int/gb/ebwha/pdf_files/EB134/B134_28-en.pdf.

⁷⁶ Katrien Moens, MSC, et al., "Are There Differences in the Prevalence of Palliative Care-Related Problems in People Living With Advanced Cancer and Eight Non-Cancer Conditions?," *Journal of Pain and Symptom Management*, pp. 667-668; WHO, "Morocco: Noncommunicable Disease (NCD) Country Profile," http://www.who.int/nmh/countries/mar_en.pdf?ua=1 (accessed July 29, 2015).

Suffering Caused by Untreated Pain

My mother would cry out in pain. My mother is a very strong woman. She wanted to reach inside her own body to take the pain away.

—Daanya Kassem, daughter of a woman with abdominal cancer⁷⁷

As noted above, pain has devastating physical, psychological, and social consequences for the people it affects and their loved ones. In interviews with Human Rights Watch, patients in Morocco who had experienced pain described in stark terms these consequences and the resulting suffering.

Adil Akram, a 29-year-old man who battled cancer in his leg for years, told Human Rights Watch: “Four months ago I started feeling pain.... Because of the pain I couldn’t sleep. I couldn’t talk to my friends. I wanted to crush my head against the wall and shake.... My pain tears me apart.”⁷⁸ Adil said that the pain made it difficult for him to sleep, move around, and eat, and had forced him to stop working. He had become socially isolated, no longer wanting to meet with friends or loved ones.

Habib Saad, a 59-year-old man with lung cancer, echoed Adil’s story: “I just endured the pain, barely sleeping, barely watching television, barely talking to my family.... [When I’m in pain], I can’t think about anything. I think only about myself.”⁷⁹

Pain also takes a heavy toll on caregivers. Maya Jalali, for example, the daughter of Haydar Jalali, a man with abdominal cancer, described the heavy burden of watching her father in pain without being able to help. She told Human Rights Watch:

Before the morphine, he couldn’t sleep, he couldn’t even sit.... He used to scream all the time and would require us to stay with him.... When you see someone feeling pain, you feel pain too. He is your father and you don’t know what to do to help him. If I could take part of the pain, I would.⁸⁰

⁷⁷ Human Rights Watch interview with Daanya Kassem (pseudonym), October 1, 2014.

⁷⁸ Human Rights Watch interview with Adil Akram (pseudonym), October 1, 2014.

⁷⁹ Human Rights Watch interview with Habib Saad (pseudonym), September 30, 2014.

⁸⁰ Human Rights Watch interview with Maya Jalali (pseudonym), January 12, 2015.

Delayed Access to Palliative Care

Some patients have received pain treatment before arriving here, but there is morphineophobia in Morocco. Before patients come here, they would usually only get paracetamol, tramadol, or codeine. Sometimes that is inadequate—frequently we need to prescribe morphine.

—Medical oncologist, regional oncology center⁸¹

Many people we interviewed described significant delays in accessing palliative care. As it is available only in a few major cities, these people initially sought care at hospitals that did not have any staff trained in providing this health service and who, as a result, did not properly assess or treat their symptoms. These people described severe suffering and intense anguish as the doctors at these healthcare institutions struggled to attend to their urgent health needs. The case of Zayan Ebrahim, presented in the summary, is illustrative.

Even at hospitals that do have trained palliative care physicians, patients may suffer significant untreated pain when they are not referred in a timely manner. For example, Aadam Khalil, a 75-year-old imam with skin cancer that had spread to his prostate and bones, experienced pain for several months before his treating physician at one of Morocco's regional oncology centers sent him to the palliative care unit. We interviewed Aadam's son-in-law, Mahmud, because Aadam could not speak due to his illness.

Mahmud told Human Rights Watch that Aadam had been receiving curative treatment at a regional oncology center when he began to experience severe pain. Although the hospital had a palliative care specialist, his physician initially did not refer him but tried to manage his symptoms himself. Mahmud said:

He has pain in his arms and private parts. He only cries when he suffers pain. He cannot speak.... He was suffering with pain for six months before receiving morphine. The doctors administered other sorts of medications before the morphine. They were not adequate. Maybe they would take away the pain for a few minutes.⁸²

⁸¹ Human Rights Watch interview with a medical oncologist (name withheld), regional oncology center, January 26, 2015.

⁸² Human Rights Watch interview with Mahmud El-Sayed (pseudonym), January 19, 2015.

When Human Rights Watch saw Aadam he had eventually been sent to the palliative care specialist. Mahmud said treatment of his father-in-law's pain had improved, but was still not fully under control.

Physicians echoed this testimony. Dr. Zakaria Belkhadir, chief of anesthesiology at the National Oncology Institute in Rabat, told Human Rights Watch: "We see a lot of patients who arrive on paracetamol and they need stronger pain medications. But doctors [especially outside of the main city] don't prescribe morphine."⁸³ Dr. Laila Hessissen of the children's hospital in Rabat said: "When patients come in from other areas they often come into [the hospital] with pain. The first thing people do is ask for pain treatment."⁸⁴

Long Distances to Palliative Care Providers

We are only at the beginning of our goal, which is to provide people experiencing the most difficult times in their lives the opportunity to receive appropriate care nearby their families.

—Dr. Mati Nejmi, former chief of anesthesiology at the National Oncology Institute in Rabat⁸⁵

As only a few specialty hospitals in Morocco offer palliative care, many patients who require it live far from the nearest provider. This means they often have to travel long distances to access palliative care, frequently on public transport. For curative care, the cost and inconvenience of such travel may be unavoidable as primary and many secondary care facilities do not have the specialists, diagnostic equipment, and/or laboratory capacity to properly manage patients with complex illnesses. This is not true, however, for palliative care, which for most patients does not require any complex interventions and can be easily and inexpensively provided at lower levels of care.

Morocco's Sectoral Health Strategy and National Cancer Prevention and Control Plan clearly both call for decentralized palliative care provision and the establishment of

⁸³ Human Rights Watch interview with Dr. Zakaria Belkhadir, Chief of Anesthesiology, National Oncology Institute, Rabat, January 28, 2015.

⁸⁴ Human Rights Watch interview with Dr. Laila Hessissen, pediatric oncologists, Rabat, September 30, 2014.

⁸⁵ Youssef Sourgo, "Creation of the First Unit for Palliative Care in a Private Clinic in Casablanca," *Morocco World News*, June 5, 2013.

palliative care networks. Yet, palliative care services have not yet been decentralized, making it impossible for many people to receive it close to their homes.

Distance poses a dilemma for patients, particularly for patients with advanced illness for whom travel can become increasingly difficult—if not impossible. They often end up having to choose between three unenviable options:

- Enduring the hardships of traveling, even in a fragile condition, in order to receive optimal care;
- Sending relatives—often their only caregivers—to get medications. In such cases, they do not see the physician themselves, compromising the ability of the palliative care team to provide proper care; or
- Staying home and getting no care at all.

The cost of travel is a second dilemma. Patients and their families have often already incurred extensive costs, frequently accumulating considerable debt, paying for diagnostic tests and curative care. Even when the palliative care services and medications are offered free of charge, travel often drives them deeper into poverty.

Various people interviewed by Human Rights Watch described the hardships of having to travel long distances to get access to palliative care and pain management. Maya Jalali told Human Rights Watch she had to frequently make the 120km trips from her home in central Morocco to receive palliative care medications for her father:

I only come to get medication, or when his pain is difficult to control. I take a bus. When I'm bringing my father, I take a private car because the bus is uncomfortable for him and the station is far from the hospital... When I come alone, I pay 150 MAD (US\$15.71). More when my father comes.

She said that she had stopped working when her father became ill, making the cost of transportation all the more burdensome.⁸⁶

Rajiya Azam, the daughter of Luja Azam, a 75-year-old women with pancreatic cancer from Beni Mellal, central Morocco, echoed this sentiment. She said:

⁸⁶ Human Rights Watch interview with Maya Jalali (pseudonym), January 12, 2015.

I have to come here for the medications. There is not a place near me to get them. Each time I come it's a little different, sometimes I rent a car, sometimes I borrow a car, sometimes I take the bus. It takes about three hours by car and four hours by bus.⁸⁷

Because of the long distances traveled to access palliative care services, many patients do not come to the hospital at all or as frequently as necessary. This creates significant challenges for palliative care providers and may result in lower quality care for the patient. As Dr. Asmaa El Azhari, the head of the palliative care unit at the regional oncology center in Casablanca, noted:

Apart from the difficulty for patients having to come all the way to Casablanca, I must manage these patients by phone. If a patient's son call me and says, "the pain has gotten worse," I don't know why the pain has gotten worse and what I should do to treat it.⁸⁸

Another important consequence of the lack of a decentralized approach to palliative care is the fact that highly specialized healthcare providers at tertiary hospitals end up caring for patients with health issues that could be addressed at lower levels of the healthcare system. This limits their capacity to treat patients with complex symptoms, to conduct research, and to teach—all critical functions of specialists as identified in Morocco's National Cancer Prevention and Control Plan.⁸⁹

Recognizing the burden excessive travel has on patients, the WHO recommends the provision of community-based palliative care. In line with that goal, Professor Abdellatif Benider, the chief oncologist at Casablanca's regional oncology center said: "In Morocco the characteristic of the family is that they show solidarity. They prefer the patient to die in their home. But they need the assistance of doctors."⁹⁰ Professor Khalid Hassouni, the chief oncologist at Fez's regional oncology center, describing his desire to develop home-based care in Fez, adds: "I

⁸⁷ Human Rights Watch interview with Rajiya Azam (pseudonym), January 12, 2015.

⁸⁸ Human Rights Watch interview with Dr. Asmaa El Azhari, head of the palliative care unit at the regional oncology hospital in Casablanca, Casablanca, October 1, 2014.

⁸⁹ Ministry of Health and Lalla Salma Foundation, "National Cancer Prevention and Control Plan" ("Plan Nationale de Prévention et de Contrôle Du Cancer"), measure 70, http://www.contrelecaner.ma/site_media/uploaded_files/PNPCC_-_Axes_strategiques_et_mesures_2010-2019.pdf.

⁹⁰ Human Rights Watch interview with Pr. Abdellatif Benider, Chief of Oncology, regional cancer center, Casablanca, January 21, 2015.

just don't want to see patients suffer. I don't tolerate this. It is better to treat patients at their homes with their family. It's difficult for them to come to the hospital.”⁹¹

The Positive Effect of Palliative Care on Patients' Lives

I thank God for morphine. My life is better.

—Rabail Mannan, 30-year old women with cervical cancer⁹²

As noted above, palliative care providers can generally control symptoms from life-limiting illnesses well, often with basic medications and interventions. Morphine and other opioid analgesics are highly effective in relieving cancer pain. Similarly, basic counseling and other palliative care interventions can prevent or greatly mitigate suffering due to psychosocial and other symptoms. Several of the people we interviewed told us how dramatically their quality of life had improved once they received access to palliative care services and their pain or other symptoms were under control.

For example, Habib Saad, a man with lung cancer, told Human Rights Watch: “I would die if not for the [palliative care unit]. There's no other place I can go.... I'm happy because I'm [mostly] free of pain.”⁹³

Jaleel Mannan, a 40-year-old women with breast cancer, shared this sentiment:

Because of the pain, I could not sleep. I could not even drink water. The pain started at my abdomen and went down to my feet.... My pain was a ten. Now the pain is a five. If it wasn't for the medications, I couldn't stay here and talk to you. Now from time to time I feel pain, but it was nothing like it was during the time before I received morphine.⁹⁴

⁹¹ Human Rights Watch interview with Pr. Khalid Hassouni, Chief of Oncology, regional oncology center, Fez, January 28, 2015.

⁹² Human Rights Watch interview with Rabail Mannan (pseudonym), October 1, 2014.

⁹³ Human Rights Watch interview with Habib Saad (pseudonym), September 30, 2014.

⁹⁴ Human Rights Watch interview with Jaleel Mannan (pseudonym), January 12, 2015.

III. Barriers to Accessing Palliative Care in Morocco

The WHO and its decision-making body, the World Health Assembly (WHA), recommend the integration of palliative care into national health systems. To achieve this, the WHO recommends that governments formulate and implement a number of specific policies that it considers essential for expanding palliative care, including:

- Health system policies to ensure the integration of palliative care into the structure and financing of national health care systems at all levels of care;
- Policies for strengthening and expanding human resources, including education and training of health care professionals, in order to ensure adequate responses to the palliative care needs, together with training of volunteers and education of the public;
- A medicines policy in order to ensure the availability of essential medicines for the management of symptoms, including pain and psychological distress, and in particular, opioid analgesics for relief of pain and respiratory distress; and
- A policy for research into assessing the needs for palliative care and identifying standards and models of service that work, particularly in limited resource settings.⁹⁵

The WHO has noted that such measures, fundamental for the development of palliative care, “cost very little but can have a significant effect.”⁹⁶ A WHA resolution on palliative care unanimously adopted on May 23, 2014, closely mirrors these recommendations.⁹⁷

These recommendations also correspond closely with several obligations under the right to health. The Committee on Economic, Social and Cultural Rights, the body that monitors the implementation of the right to health as articulated in the International Covenant on Economic, Social and Cultural Rights (ICESCR),⁹⁸ has held that countries must adopt and

⁹⁵ WHO, “Strengthening of Palliative Care as a Component of Integrated Treatment throughout the Life Course,” no. 19, http://apps.who.int/gb/ebwha/pdf_files/EB134/B134_28-en.pdf.

⁹⁶ WHO, “Cancer Pain Relief,” p. 3, <http://whqlibdoc.who.int/publications/9241544821.pdf>

⁹⁷ WHA resolution 67.19, “Strengthening of Palliative Care as a Component of Comprehensive Care throughout the Life Course,” May 14, 2014, http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R19-en.pdf (accessed June 26, 2014).

⁹⁸ International Covenant on Economic, Social and Cultural Rights (ICESCR), adopted December 16, 1966, G.A. Res. 2200A (XXI), 21 U.N. GAOR Supp. (No. 16) at 49, U.N. Doc. A/6316 (1966), 993 U.N.T.S. 3, entered into force January 3, 1976, art. 12;

implement a national public health strategy and plan of action and ensure access to essential medicines as defined by the WHO.⁹⁹ It has identified providing appropriate training for health personnel as an obligation “of comparable priority.”¹⁰⁰ Failure to take steps in these areas may result in a violation of the right to health.

Integrating Palliative Care into the Healthcare System

According to the WHO, national health system policies should promote the integration of palliative care into the structure and financing of national healthcare systems at all levels of care. In these policies, the emphasis should be on primary, community, and home-based care.¹⁰¹

The right to health requires states to take the steps necessary for the “creation of conditions which would assure *to all* medical service and medical attention in the event of sickness” (emphasis added).¹⁰² The Committee on Economic, Social and Cultural Rights has held that people are entitled to a “system of health protection which provides equality of opportunity for people to enjoy the highest attainable level of health.”¹⁰³ In other words, health services should be available for all health conditions, including chronic or terminal illness, on an equitable basis.

The basic idea behind the WHA resolution and WHO recommendations is that patients should receive palliative care as close to their homes as possible. A patient who receives curative cancer treatment at a tertiary care facility should be able to receive palliative care at that facility while in curative treatment but should, if their condition allows, be referred to their primary care provider near their home should their cancer become incurable. Conversely, a palliative care patient who is attended to at primary care level but has

Convention on the Rights of the Child (CRC), G.A. res. 44/25, annex, 44 U.N. GAOR Supp. (No. 49) at 167, U.N. Doc. A/44/49 (1989), entered into force September 2, 1990, art. 12.

⁹⁹ UN Committee on Economic, Social and Cultural Rights, “Substantive Issues Arising in the Implementation of the International Covenant on Economic, Social and Cultural Rights,” General Comment No. 14, The Right to the Highest Attainable Standard of Health, E/C.12/2000/4 (2000), para. 43, <http://www.unhcr.ch/tbs/doc.nsf/%28symbol%29/E.C.12.2000.4.En> (accessed May 14, 2015).

¹⁰⁰ *Ibid.*, para 44(f).

¹⁰¹ WHO, “Strengthening of Palliative Care as a Component of Integrated Treatment throughout the Life Course,” p 20(i), http://apps.who.int/gb/ebwha/pdf_files/EB134/B134_28-en.pdf.

¹⁰² ICESCR, art. 12 (2).

¹⁰³ UN Committee on Economic, Social and Cultural Rights, General Comment No. 14, para 8.

complex symptoms that a primary caregiver cannot properly address should be referred to secondary or tertiary levels of care.

To receive palliative care near their home, patients must have access to a doctor who is trained to treat at least basic symptoms common in patients with life-limiting illnesses and has the ability to prescribe essential medications for the treatment of these symptoms. At higher levels of care, where many patients with complex symptoms are seen, multidisciplinary palliative care teams should be available.

Morocco has clearly identified developing palliative care as a priority. Its Sectoral Health Strategy (SHS) for 2012-2016 and National Cancer Prevention and Control Plan (NCPCP) for 2010-2019 set out a vision for the development of a palliative care system that is broadly aligned with WHO and WHA recommendations. The documents call for the creation of palliative care networks; the development of external palliative care consultations; and the institutionalization of pain treatment at all levels of the healthcare system.

The NCPCP notes that “an overview of palliative care reveals major problems” that need to be addressed, identifying, among others:

- Insufficient training of professionals in the palliative care field;
- Lack of human resources: doctors, nurses, physiotherapists, auxiliary nurses, etc.;
- Lack of recovery centers adapted to general and terminal palliative care;
- Insufficient follow-up of palliative care after return to the home; and
- Absence of supportive care and civic culture regarding end-of-life and death issues.¹⁰⁴

The NCPCP sets two ambitious goals, to be achieved by 2019: “To have a nationwide palliative care network” and “support 100 percent of [cancer] patients requiring palliative care.”¹⁰⁵ The SHS does not provide any analysis of the current palliative care situation or set specific goals, although the action points it identifies are similar to those of the NCPCP (see Sectoral Health Strategy text box).

¹⁰⁴ Ministry of Health and Lalla Salma Foundation, “National Cancer Prevention and Control Plan” (“Plan Nationale de Prévention et de Contrôle Du Cancer”), p. 45, http://www.contrelecaner.ma/site_media/uploaded_files/PNPCC_-_Axes_strategiques_et_mesures_2010-2019.pdf.

¹⁰⁵ Ibid.

The NCPCP contains a detailed breakdown of specific measures required to realize the broad vision for Morocco’s palliative care system for people with cancer, organized in four categories: develop pain management; ensure family and social assistance; ensure development and extension of care networks in palliative care; and develop research on palliative care.

These action points cover each of the four areas—policy, education, medicine availability, and research—that the WHO identifies as essential for the development of palliative care and support a decentralized approach to palliative care. For example, the measures under the category on pain management cover the institutionalization of pain management across the healthcare system; legal and regulatory change to improve access to pain medicines; development of educational materials and protocols; and public information campaigns to educate the public.

The NCPCP, however, does not clearly determine a specific timeline or determine what government or other agencies are responsible for the implementation of these measures, except for the construction of palliative care units in Casablanca, Marrakesh, and Fez, planned for 2011-2013 (the palliative care centers in Marrakesh and Fez have not yet been built).¹⁰⁶

The plan allocates a total of 86 million MAD (approximately US\$8.7 million) to the implementation of the palliative care components over the course of the 10-year period it covers, including 5 million MAD for developing pain management, 6 million for social support, and 75 million for developing the palliative care network.¹⁰⁷ No budget is allocated to palliative care research. The budget does not indicate which government agencies will receive these funds.

The budget allocations for palliative care make up 1 percent of the overall budget under the NCPCP—compared to 88 percent for diagnosis and curative treatment.¹⁰⁸ This seems a paltry sum given that the NCPCP itself recognizes that the difficulties with access to

¹⁰⁶ Ibid., p. 59.

¹⁰⁷ Ibid., p. 68.

¹⁰⁸ This figure does not include funds spent on human resources, such as palliative care doctors at the national oncology institute. Letter from Dr. Abdelali Belghiti Alaoui, secretary general, Ministry of Health, to Human Rights Watch, June 4, 2015. It is also likely that some of the resources allocated to diagnosis and treatment will benefit patients in need of palliative care. For example, the establishment of new cancer centers, even if primarily focused on diagnosis and curative care, will also attend to patients requiring palliative care. Similarly, it is possible that essential palliative care medicines are purchased under the budget allocation for medicines.

healthcare services results in many patients being “diagnosed at very advanced stages of the disease,” when curative interventions are of limited utility.¹⁰⁹ According to Dr. Mati Nejmi and Dr. Laila Hessissen, 60-70 percent of cancer patients are diagnosed in late stages of the disease.¹¹⁰ The NCPCP notes that 96 percent of individuals with lung cancer, the most common form of cancer in Moroccan men, are diagnosed in stages III and IV.¹¹¹

In contrast to the Moroccan plan, the WHO has pointed out that in “countries with limited resources, it is not logical to provide extremely expensive therapies that may benefit only a few patients, while the majority of patients presenting with advanced disease and urgently in need of symptom control must suffer without relief.”¹¹²

Given the above, it is perhaps not surprising that Human Rights Watch’s analysis of the implementation effort—to the extent we have been able to check progress given limitations on our access to healthcare facilities and government officials—has found that, more than halfway through the NCPCP’s cycle, progress has been uneven and limited in many areas. A number of key findings include:

- Little progress has been made to date on the development of the decentralized palliative care network the NCPCP envisions. While a palliative care center was created in Casablanca, none have been anywhere else in the country;
- Opioid analgesics remain largely unavailable outside tertiary health facilities. The controlled substances law has been amended to increase the maximum prescription period for opioid analgesics, but few steps have been taken to counter physicians’ and pharmacists’ fears and misconceptions around these medicines or to increase the number of physicians with prescription privileges;
- Limited progress toward the decentralization of pain management. Our research suggests pain management committees at regional and provincial hospitals have either not yet been established or are not functioning effectively; and

¹⁰⁹ Ministry of Health and Lalla Salma Foundation, “National Cancer Prevention and Control Plan” (“Plan Nationale de Prévention et de Contrôle Du Cancer”), p. 28, http://www.contrelecancer.ma/site_media/uploaded_files/PNPCC_-_Axes_strategiques_et_mesures_2010-2019.pdf.

¹¹⁰ Nejmi and Hessissen, “Moroccan Experience,” p. 143.

¹¹¹ Ministry of Health and Lalla Salma Foundation, “National Cancer Prevention and Control Plan” (“Plan Nationale de Prévention et de Contrôle Du Cancer”), p. 28, http://www.contrelecancer.ma/site_media/uploaded_files/PNPCC_-_Axes_strategiques_et_mesures_2010-2019.pdf.

¹¹² WHO, “National Cancer Control Programme,” p. 86, <http://www.who.int/cancer/media/en/408.pdf>.

- While NCPCP identifies developing research on palliative care needs and practices as an area for action, we were unable to identify any efforts by the government to conduct research on palliative care. The NCPCP does not allocate any budget to palliative care research.

THE SECTORAL HEALTH STRATEGY

In 2012, Morocco adopted a Sectoral Health Strategy (SHS) for 2012-2016 that focuses on a number of key health priorities for the country, including access to health services, maternal and child health, care for vulnerable populations, epidemiological surveillance, non-communicable diseases, development of resources, and health governance. The strategy formulates action points for each of these areas.

The section on non-communicable diseases (NCDs) sets out a number of action points on pain treatment and palliative care. In particular, it states:

Action 80: Establishment of a pain management strategy.

- Institutionalization of pain management at all levels of intervention (hospital, outpatient, home);
- Training and information for healthcare personnel and fight against morphinophobia;
- Development of “pain centers” in CHUs (University Hospital Centers);
- Establishment of pain-management committees in regional and provincial hospitals; and
- Establishment of territorial healthcare networks dedicated to pain management.

Action 81: Establishment of a palliative-care development strategy.

- Development of outside consultation for palliative care and setup of regional telephone branches specialized in providing advice;
- Family and social assistance; and
- Establishment of territorial healthcare networks dedicated to palliative and supportive care.¹¹³

Action 80 and 81 are critically important to addressing the needs of non-cancer patients who require palliative care and were welcomed by the INCB.¹¹⁴ While they identify the elements of palliative care and pain treatment strategies, it is not clear who should develop the actual strategies and implement them, nor does the SHS specify a budget for doing so. To date, these strategies have not yet been developed.

¹¹³ Ministry of Health, “Sectoral Strategy for Health 2012-2016” (“Strategy Sectorielle de Santé 2012-2016”), arts. 80-81, <http://www.sante.gov.ma/Docs/Documents/secteur%20sant%C3%A9.pdf>.

¹¹⁴ INCB, Annual Report, 2012, p. 19, https://www.incb.org/documents/Publications/AnnualReports/AR2012/AR_2012_E.pdf (accessed July 8, 2015).

With four-and-a-half years left in the cancer strategies cycle, however, the government still has an opportunity to refocus its efforts and make considerable progress towards its palliative care goals. Significantly, the Ministry of Health told Human Rights Watch that they are undertaking a review of the NCPCPs progress to date and anticipate that palliative care will arise as a priority issue.¹¹⁵

Integrating Palliative Care into Healthcare Financing

Although the right to health does not require states to offer health services and medications free of charge, they should be “affordable for all.”¹¹⁶ The WHO adds that the use of palliative care services “must not lead to financial hardship, especially among ... populations living in vulnerable situations” and recommends that national health systems promote the integration of palliative care into healthcare financing as part of efforts to promote universal health coverage.¹¹⁷ Since 2011, Morocco’s constitution explicitly recognizes a right to health coverage for its citizens, but to date, health insurance schemes cover only about 50 percent of the population.¹¹⁸ The remainder of the population has to pay for health services out of pocket.

Palliative Care Coverage under Morocco’s Insurance Schemes

In principle, both of Morocco’s public insurance schemes, RAMED and AMO, cover the provision of palliative care. Our research, however, found that coverage of palliative care for many RAMED and AMO clients is not effective. In other words, while palliative care is theoretically covered, they cannot actually get it or key elements are not included in the coverage.

The biggest single impediment to effective insurance coverage of palliative care is the fact that the number of healthcare providers that offer it is extremely limited. People with cancer who live outside major cities have no option but to travel in order to receive care. For patients who require palliative care for other illnesses, the services are almost entirely unavailable. Patients with AMO could seek care from private palliative care providers, as

¹¹⁵ Letter from Dr. Abdelali Belghiti Alaoui, secretary general, Ministry of Health, to Human Rights Watch, June 4, 2015.

¹¹⁶ UN Committee on Economic, Social and Cultural Rights, General Comment No. 14, para. 12.

¹¹⁷ WHO, “Strengthening of Palliative Care as a Component of Integrated Treatment throughout the Life Course,” no. 10, http://apps.who.int/gb/ebwha/pdf_files/EB134/B134_28-en.pdf.

¹¹⁸ The Constitution (“La Constitution”), July 29, 2011, art. 34, http://www.amb-maroc.fr/constitution/Nouvelle_Constitution_%20Maroc2011.pdf (accessed May 14, 2015).

their insurance covers service provided by private hospitals, but there is only one known private palliative care service in the country.

As noted above, RAMED covers medications used during hospitalization as long as they are included within a list of reimbursable medicines. However, it provides no coverage for medications prescribed to outpatients (cancer patients who are receiving outpatient care at regional cancer centers can get free medications through the joint Lalla Salma Foundation/Ministry of Health ACCESS program).¹¹⁹ Thus, outpatients with RAMED coverage have to fill prescriptions at private pharmacies even for medications that are on the RAMED list. As palliative care patients tend to receive most of their care as outpatients, this significantly limits the effectiveness of the coverage of palliative care through RAMED.¹²⁰ AMO does cover medicines prescribed to outpatients and provides patients with substantial reimbursements.

Finally, neither RAMED nor AMO covers any costs incurred by patients who need to travel to other cities in order to receive care or treatment that is not available where they live. As noted above, the fact that palliative care services are only available in major cities means that many patients or their relatives must travel long distances, sometimes as far as five hours, to receive palliative care. One patient noted that her monthly trips to the regional oncology center cost 150 MAD (US\$15.71) or more, roughly two-thirds of the monthly cost of the morphine she was purchasing.¹²¹ Measure 68 of the NCPCP recognizes the burden of travel expenses borne by patients and calls for “financial coverage for safe transport from the hospital to the home, and from the home to the hospital.”¹²²

¹¹⁹ Lalla Salma Foundation, “Results 2006-2010” (“Bilan 2006-2010”), pp. 54-57, http://www.contrelecancer.ma/site_media/uploaded_files/ALSC_-_Bilan_2006-2010.pdf.

¹²⁰ This issue is not unique to palliative care. For example, Yazeed Amini, the husband of a woman with cervical cancer, told Human Rights Watch about the difficulty he had obtaining chemotherapy medications. He said: “I’m on RAMED so the medications would be free, but when I took the prescription to the hospital pharmacy, they said they didn’t have it. [I went to a] charitable organization to get assistance with the cost of the medication, but it is not available from them either. If I can’t get the medication by tomorrow, they will have to push my wife’s chemotherapy back.” Human Rights Watch interview with Yazeed Amini (pseudonym), January 26, 2015.

¹²¹ Human Rights Watch interview with Maya Jalali (pseudonym), January 12, 2015. Maya’s father was receiving 10mg of time-release morphine twice daily. A box of 12, 10mg time-release morphine tablets at a private pharmacy in Rabat costs 46 MAD. Maya’s father’s medication, but not travel, was covered by the ACCESS program.

¹²² Ministry of Health and Lalla Salma Foundation, “National Cancer Prevention and Control Plan” (“Plan Nationale de Prévention et de Contrôle Du Cancer”), p. 28, http://www.contrelecancer.ma/site_media/uploaded_files/PNPCC_-_Axes_strategiques_et_mesures_2010-2019.pdf.

INTEGRATING PALLIATIVE CARE INTO THE HEALTHCARE SYSTEM: PANAMA

Through a combination of legal and regulatory reform, Panama, a middle-income country, has taken large strides to improve access to palliative care. Panamanian law grants patients a right to receive palliative care, requires all hospitals to have palliative care units, and places responsibility on primary health centers for providing palliative care to patients who require it over extended periods of time.¹²³ In 2011, Panama's Health Ministry adopted a national palliative care strategy to help implement the law.¹²⁴

The philosophy behind the strategy is that patients should always receive care as close to home as possible. It sets out a model that links the different levels of the healthcare system so that patients can move easily between them depending on their situation. A key role in this model is assigned to Panama's regional hospitals, all of which must have multidisciplinary palliative care teams. These teams not only offer clinical care but are responsible for training healthcare workers at the primary level of care; offering them ongoing support in the care for patients; and working with nongovernmental groups, such as NGOs and churches, to develop community support for palliative care. The multidisciplinary teams are also the link between the different levels of care, facilitating referrals up and down the chain.

Panama has made significant progress with implementing this strategy. Each of the country's nine regions has a palliative care coordinator, more than half of the regions have active palliative care programs, and the number of patients receiving palliative care has risen steadily. Even so, challenges remain, especially in remote regions, within the social security system, and in the provision of palliative care to children.¹²⁵

Palliative Care Education for Healthcare Workers

[Doctors] are not aware of the importance of palliative care. We must add palliative care now to the training of doctors.... If we start now, the next generation of doctors will all know how to [provide] palliative care.

—Dr. Mati Nejmi, former chief of anesthesiology at the National Oncology Institute in Rabat

¹²⁶

¹²³ See article 23 of Law 68 of November 20, 2003, <http://www.gorgas.gob.pa/wp-content/uploads/2013/11/Ley-68-2003-Regula-los-derechos-y-obligaciones-de-los-pacientes.pdf> (accessed May 14, 2015).

¹²⁴ Ministerio de Salud de Panamá, "National Palliative Care Program" ("Programa Nacional de Cuidados Paliativos"), 2011, [http://190.34.154.93/mcp/sites/all/files/Cuidados%20paliativos%20\(2\).pdf](http://190.34.154.93/mcp/sites/all/files/Cuidados%20paliativos%20(2).pdf) (accessed May 15, 2015).

¹²⁵ Human Rights Watch email correspondence with Dr. Gaspar Da Costa, Panama's national palliative care coordinator, September 10, 2014.

¹²⁶ Human Rights Watch interview with Dr. Mati Nejmi, Rabat, September 29, 2014.

Adequate training and education for healthcare workers in palliative care is essential to rolling out this healthcare service.¹²⁷ Indeed, in many countries, the lack of such training is the single greatest barrier to providing palliative care.

The Committee on Economic, Social and Cultural Rights considers appropriate training of healthcare workers an obligation of key importance.¹²⁸ Accordingly, the WHO recommends that “education about palliative care (including ethical aspects) is offered to students in undergraduate medical and nursing schools and to healthcare providers at all levels...”¹²⁹ The May 2014 World Health Assembly resolution calls on countries to include palliative care as an “integral component of the ongoing education and training offered to care providers” and specifies:

- a. basic training and continuing education on palliative care should be integrated as a routine element of all undergraduate medical and nursing professional education, and as part of in-service training of caregivers at the primary care level, including health care workers, caregivers addressing patients’ spiritual needs and social workers;
- b. intermediate training should be offered to all health care workers who routinely work with patients with life-threatening illnesses, including those working in oncology, infectious diseases, paediatrics, geriatrics and internal medicine; and
- c. specialist palliative care training should be available to prepare health care professionals who will manage integrated care for patients with more than routine symptom management needs.¹³⁰

The European Association for Palliative Care (EAPC) has developed a model curriculum for undergraduate and specialist palliative care training. It recommends that undergraduate medical students receive 40 hours of training in palliative care and pain management, including some clinical aspects of palliative care, and should be tested on their knowledge

¹²⁷ European Association for Palliative Care (EAPC), “Specialization in Palliative Medicine for Physicians in Europe 2014: A Supplement to the EAPC Atlas of Palliative Care in Europe,” 2014, preface, http://www.eapcnet.eu/Portals/0/Organization/Development%20in%20Europe%20TF/Specialisation/2014_SpecialisationPMPPhysicianInEurope.pdf (accessed May 15, 2015); David Clark, “International Progress in Creating Palliative Medicine as a Specialized Discipline,” in *Oxford Textbook of Palliative Medicine, Fourth Ed.*, ed. Geoffrey Hanks, et al., (London: Oxford University Press, 2010), p. 10.

¹²⁸ UN Committee on Economic, Social and Cultural Rights, General Comment No. 14, para. 44.

¹²⁹ WHO, “Strengthening of Palliative Care as a Component of Integrated Treatment throughout the Life Course,” para. 20, http://apps.who.int/gb/ebwha/pdf_files/EB134/B134_28-en.pdf.

¹³⁰ WHA resolution 67.19, “Strengthening of Palliative Care as a Component of Comprehensive Care Throughout the Life Course.”

of the subject matter.¹³¹ They also recommend that specialists receive an additional 40 hours of theoretical training and 160 hours of clinical training after specializing in another field, such as internal medicine.¹³² The EAPC has not made any recommendations regarding the content of intermediate level training.

This layered approach to palliative care education is essential to integrating palliative care across all levels of the healthcare system, as the WHA resolution recommends. A healthcare system in which all healthcare workers have training in palliative care appropriate for their role allows patients to receive care as close to home as possible, thus sparing them arduous, expensive, and time-consuming trips to specialists. It also allows specialists to focus on the most complex cases while general practitioners can attend to routine ones, thus improving the efficiency of the system.¹³³ As Dr. Hessissen, a pediatric oncologist at the pediatric oncology hospital in Rabat, noted: “The best doctor to manage the patients is the proximate doctor. [But they] need to be trained.”¹³⁴

Medical Education

Undergraduate Training

Morocco has five public universities with medical school programs located in Rabat, Casablanca, Marrakesh, Fez, and Oujda. Obtaining a degree in medicine from one of these universities involves a seven-year education and training program.¹³⁵ The first five years of the program consist mainly of theoretical instruction in essential sciences and medicine.¹³⁶ In the sixth and seventh year, students engage in a full-time externship and internship positions.¹³⁷

¹³¹ EAPC, “Recommendations of the European Association for Palliative Care (EAPC) for the development of Undergraduate Curricula in Palliative Medicine at European Medical Schools,” 2013, p. 10.

¹³² EAPC, “Recommendations of the European Association of Palliative Care for the Development of Postgraduate Curricula Leading to Certification in Palliative Care,” 2009, p. 9, <http://www.eapcnet.eu/LinkClick.aspx?fileticket=2DHXbM1zaMI%3D> (accessed July 29, 2015).

¹³³ Timothy E. Quill, M.D. and Amy P. Abernethy, M.D., “Generalist Plus Specialist Palliative Care—Creating a More Sustainable Model,” *New England Journal of Medicine*, vol. 368, no. 13 (2013), pp. 1173-74; http://www3.med.unipmn.it/papers/2013/NEJM/2013-03-28_nejm/nejmp1215620.pdf (accessed May 15, 2015); Human Rights Watch interview with Dr. Asmaa El Azhari, Casablanca, October 1, 2014.

¹³⁴ Human Rights Watch interview with Dr. Laila Hessissen, Rabat, September 30, 2014.

¹³⁵ Fixant la Régime des Etudes et des Examens en vue de l’Obtention du Diplôme de Docteur en Médecine, no 2.82.356 of 1983, art. 2. http://www.enssup.gov.ma/doc_site/documents/Txt_juridiques/etudes/dec_2_82_356.pdf (accessed December 3, 2014).

¹³⁶ *Ibid.*, arts. 8-10.

¹³⁷ *Ibid.*, arts. 22-23.

Prior to 2015, as noted in Human Rights Watch's 2011 report on the global state of pain treatment, palliative care had not been formally integrated into the undergraduate curricula for medical students.¹³⁸ While some medical schools offered content that touched on palliative care, there were no mandatory courses on the topic.¹³⁹ As a result, most current physicians in Morocco have no or limited knowledge of palliative care and lack any clinical exposure to this health service, greatly complicating efforts to integrate palliative care into the healthcare system.

This is about to change. Based on a recommendation by a joint Ministry of Health and the Ministry of Higher Education commission established in 2005 to reform medical studies in Morocco, the government is introducing changes to the national medical curriculum, which all public medical schools and two private medical schools located in Casablanca and Rabat must follow. Under the new curriculum, which will be taught starting in late-2015, all medical students will receive 20 hours of mandatory instruction on pain and palliative care during the fifth year of their medical training.¹⁴⁰

As far as Human Rights Watch is aware, at time of writing, the exact content of the palliative care component of the new curriculum has yet to be developed. For successful implementation, it is essential that experienced palliative care providers participate in that process; that they teach the content to medical students; and that palliative care is included in examinations of the students. The new curriculum also does not include mandatory clinical exposure in palliative care for medical students in their final two years. Clinical work should be progressively incorporated into medical students' training.

Although it will take some time for doctors who have taken this course to enter the workforce in meaningful numbers, the new curriculum has the potential to make a significant impact on access to pain and palliative care in Morocco. A similar 20-hour curriculum was implemented

¹³⁸ Human Rights Watch Report, *Global State of Pain Treatment: Access to Palliative Care as a Human Rights* (New York: Human Rights Watch, 2011), p. 52, <http://www.hrw.org/sites/default/files/reports/hhro511W.pdf> (accessed May 15, 2015).

¹³⁹ Ibid., appendix; Human Rights Watch interview with Dr. Mati Nejmi, September 29, 2014.

¹⁴⁰ Human Rights Watch interview with Dean Mohamed Adnaoui, Dean of the Faculty of Medicine and Pharmacy of Rabat, Rabat, January 21, 2015; Human Rights Watch email correspondence with Dean Mohamed Adnaoui, April 4, 2015; Ministry of Higher Education, Nationale Chargée Du Projet De Reforme Des Etudes Médicales, Pharmaceutiques et Odontologiques, Pour Une Nouvelle Reforme Des Etudes Médicales Au Maroc (on file with Human Rights Watch).

in France in the mid-1990s.¹⁴¹ According to the INCB, France's education reforms were a major component of its successful effort to increase access to opioids.¹⁴²

Continuing Medical Education

While the new undergraduate curriculum is a great leap forward, it is essential that Morocco also invest in training doctors who are currently practicing but have not had any training in palliative care. Developing continuing education on palliative care was a key part of the "Morocco action plan" adopted during a workshop on palliative care hosted by the WHO in collaboration with the Moroccan Society of Palliative Care and the African Palliative Care Association in 2010.¹⁴³

Unlike intermediate training, described below, continuing education should provide basic training in pain and palliative care to large portions of the medical community. The Moroccan Society of Pain and Palliative Care conducted pain management trainings in numerous cities in Morocco in 2006-2007. The trainings were held in a number of major cities across Morocco and attracted over 2000 medical practitioners.¹⁴⁴ Although impressive in their reach, these trainings focused on pain management rather than palliative care more broadly and have not been held for years.

In September of 2015, the American Society of Clinical Oncology and the regional oncology center in Fez, in collaboration with the Lalla Salma Foundation, will host a first of its kind palliative care workshop in Fez. The three-day workshop will cover a range of topics, including managing pain and other common symptoms and communicating prognosis to patients.¹⁴⁵ Although held after the writing of this report, the workshop may provide a model that can be expanded to reach larger segments of the medical profession.

¹⁴¹ Renée Sebag-Lanoë, et al., "Palliative Care in a Long-term Care Setting: a 25-year French Experience," *Journal of Palliative Care* (2003), p. 209, <http://gerontoprevention.free.fr/articles/palliativecare.pdf>; Human Rights Watch interview with Marilene Filbet, former chief of the palliative care unit in the University Hospital in Lyon, France and former president of the board of directors of the European Association of Palliative Care, November 4, 2014.

¹⁴² INCB, "Availability of Internationally Controlled Drugs: Ensuring Adequate Access to Medical and Scientific Purposes," 2010, p. 45, http://www.incb.org/documents/Publications/AnnualReports/AR2010/Supplement-AR10_availability_English.pdf (accessed May 15, 2015).

¹⁴³ WHO, et al., "Assuring the Availability and Accessibility of Opioids Medicines in the Eastern Mediterranean Region," 2010, p. 27.

¹⁴⁴ Nejmi and Hessissen, "Moroccan Experience," p. 151.

¹⁴⁵ Information about the workshop can be found here: <http://www.workshoipascofez.org> (accessed May 18, 2015).

Intermediate Training

There is a notable dearth of mandatory, intermediate training in palliative care. Human Rights Watch was able to identify one such program for doctors specializing in anesthesiology at Mohammed V University (Souissi) in Rabat. There, anesthesiology residents are required to take part in a six-month anesthesiology residency at the National Oncology Institute in Rabat, which includes a two-month rotation within the palliative care unit.¹⁴⁶

Physicians specializing in other fields of medicine that see many palliative care patients, such as oncology, internal medicine, and cardiology, do not receive any mandatory academic or clinical training in palliative care. Indeed, physicians specializing in anesthesiology in places other than Rabat do not either.

Our research was able to identify three optional certificate or diploma programs that provide intermediate training to general practitioners and specialists in pain management and/or palliative care at medical schools in Rabat, Casablanca, and Oujda. In Rabat, the university offers a one-year certificate in pain treatment and palliative care, consisting of 60-hours of theoretical course work as well as some clinical exposure to palliative care within the National Oncology Institute.¹⁴⁷

In Oujda, the university offers a diploma program, open to 30 candidates, in pain management. While the course has more training hours—120 theoretical hours and 20 “practical training” hours—than the program in Rabat, it does not offer training on palliative care.¹⁴⁸ Similarly, the pain certificate program in Casablanca does not provide course hours on palliative care.¹⁴⁹ Although these certificate or diploma programs are important for those who take advantage of them, more needs to be done to ensure that practitioners who interact frequently with palliative patients are required to receive training in *both* pain treatment and palliative care.

A major barrier to increasing intermediate training programs in palliative care for physicians who regularly encounter patients with life-limiting illnesses is the dearth of palliative care

¹⁴⁶ Human Rights Watch interview with Hamza Slimani, anesthesiology resident, Rabat, January 10, 2015.

¹⁴⁷ Nejmi and Hessissen, “Moroccan Experience,” p. 151. A description of the program can be found here: http://www.jamiati.ma/formation_continue/selon_domaine/pages/Resultat.aspx?Id_frct_cod=54 (accessed May 15, 2015).

¹⁴⁸ A description of the program can be found here: http://fmpo.ump.ma/?page_id=168 (accessed May 15, 2015).

¹⁴⁹ A description of the program can be found here:

http://www.jamiati.ma/Formation_continue/Selon_Universite/Pages/Resultat.aspx?Id_frct_cod=40134 (accessed May 15, 2015).

services in the country that can serve as resources for such programs. As Morocco increases the number of hospitals that offer palliative care, as planned under the national cancer plan, it should be possible to establish additional intermediate training programs.

Specialist Training

A ministerial decree from 1993 sets out an exhaustive list of the medical specialties available in Morocco.¹⁵⁰ In 2008, through a decree issued by the minister of higher education, internal medicine, aviation medicine, medical informatics, and pediatric psychiatry were added as medical specialties.¹⁵¹

Palliative care is not currently a medical specialty in Morocco. Beginning in 2015, Mohammed V University plans to offer a university diploma in pain and palliative care, which will include 152 hours of theoretical training on pain treatment and 28 hours on palliative care as well as a 40-hour clinical internship at the palliative care unit at the National Oncology Institute in Rabat.¹⁵² This new diploma course will be the educational opportunity closest to a medical specialty in palliative care available in Morocco, although it will not result in the title of specialist in palliative care and still falls well short of the EAPC's recommendation of 160 hours of clinical training for palliative care specialists.

Nursing Education

The World Health Assembly resolution recommends that all nursing personnel receive training in palliative care.¹⁵³ Indeed, nurses are often closest to the patients and their families and most aware of the physical and emotional symptoms patients are experiencing.¹⁵⁴ As such, they play a critical role in identifying patients who need to be referred for more complex interventions and providing basic care, assessing pain, and

¹⁵⁰ Fixant le régime des études et des examens en vue de l'obtention de diplôme de spécialité médicale, no. 2-92-182 of 1993, art. 2, <http://www.fmpm.ucam.ac.ma/data/tleg/4207.pdf> (accessed May 15, 2015).

¹⁵¹ Complétant la liste des spécialités médicales et leurs durées d'études prévues dans l'article 2 de décret no. 2-92-182 du 22 kaada 1413 (14 mai 1993), no. 412-08 of 2008, p. 478, art. 1, https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=oCB8QFjAA&url=http%3A%2F%2Fwww.cabinetseddik.com%2Factualites%2Fbulletin-officiel%2FBO_5644_Fr.pdf&ei=r9kVVaK1H4PLsASbIIcoBg&usg=AFQjCNGYYZEvQLWvL6CozxMBSb-ugTO34w&bvm=bv.89381419,d.cWc (accessed May 15, 2015).

¹⁵² Human Rights Watch email correspondence with Dr. Zakaria Belkhadir, Rabat, March 10, 2015.

¹⁵³ WHO, "Strengthening of Palliative Care as a Component of Integrated Treatment throughout the Life Course," para 20 (iv), http://apps.who.int/ebwha/pdf_files/E124/R124_28-en.pdf

¹⁵⁴ Bridget M. Johnson, "Introduction to Palliative Care: Overview of Nursing Developments," in *Palliative Care: The Nursing Role, second edition*, ed. Jean Lugton and Rosemary McIntyre (Hong Kong, Elsevier Limited, 2005), pp. 14-28.

offering social support and comfort. In Uganda, specially trained nurses are authorized to prescribe opioid analgesics to patients, which has greatly expanded access to palliative care in rural communities where no physicians are available.¹⁵⁵

There is little literature about palliative care education for nurses in Morocco. A small 2008 survey conducted at the regional oncology center in Rabat, however, suggests that palliative care training for nurses in that city was not adequate at the time. Among the 21 nurses surveyed, 20 said there were no undergraduate courses available in caring for palliative patients and 16 felt they were inadequately trained in end-of-life care. Out of all nurses surveyed, only five nurses said they had participated in any form of continuing training to care for dying patients.¹⁵⁶

Medicine Availability

The WHO recommends that countries adopt a “medicines policy in order to ensure the availability of essential medicines for the management of symptoms, including pain and psychological distress, and in particular, opioid analgesics for relief of pain and respiratory distress.”¹⁵⁷ In 2013, the WHO created sections on pain and palliative care in its Model List of Essential Medicines and its Model List of Essential Medicines for Children. These sections contain medicines and specific formulations that the WHO considers essential for pain management and palliative care.

In order to fulfill the right to health, countries should ensure the availability and accessibility of all medicines included in the WHO Model List of Essential Medicines. The Committee on Economic, Social and Cultural Rights has held that providing essential medicines as determined by the WHO is a core obligation that cannot be limited by claims of limited resources.¹⁵⁸

¹⁵⁵ Jake Jagwe, et al., “Uganda: Delivering Analgesia in Rural Africa: Opioid Availability and Nurse Prescribing,” *Journal of Pain and Symptom Management*, vol. 33, no. 5 (2007), p. 549, [http://www.jpmsjournal.com/article/So885-3924\(07\)00118-2/pdf](http://www.jpmsjournal.com/article/So885-3924(07)00118-2/pdf) (accessed May 15, 2015); Jan Stjernsward, “Uganda: Initiating a Government Public Health Approach to Pain Relief and Palliative Care,” *Journal of Pain and Symptom Management*, vol. 24, no. 2 (2002), p. 262, [http://www.jpmsjournal.com/article/So885-3924\(02\)00451-7/pdf](http://www.jpmsjournal.com/article/So885-3924(02)00451-7/pdf) (accessed May 15, 2015).

¹⁵⁶ Ali Ikrou, “La prise en charge des patients en fin de vie par le personnel infirmier cas de l’Institut National d’Oncologie sidi Mohammed ben Abdallah de Rabat,” (2008), tbl. 4, 5, http://www.memoireonline.com/12/10/4183/m_La-prise-en-charge-des-patients-en-fin-de-vie-par-le-personnel-infirmier-cas-de-linstitut-national-o.html (May 15, 2015).

¹⁵⁷ WHO, “Strengthening of Palliative Care as a Component of Integrated Treatment throughout the Life Course,” para. 19, http://apps.who.int/gb/ebwha/pdf_files/EB134/B134_28-en.pdf.

¹⁵⁸ UN Committee on Economic, Social and Cultural Rights, General Comment No. 14, para. 43.

Availability and Accessibility of Opioid Analgesics

Opioid analgesics are essential for the management of pain, shortness of breath, and several other common symptoms among people who need palliative care. Because opioid medicines are controlled substances, countries have obligations to regulate how they can be produced, distributed, prescribed, and dispensed.

In many countries, including Morocco, access to these medications is very limited. As previously mentioned, the International Narcotics Control Board noted in its 2014 annual report that 5.5 billion people live in countries with no or limited access to these medicines.¹⁵⁹

The 1961 Single Convention on Narcotic Drugs, the international agreement that provides the framework for national drug control efforts, contains four basic requirements for national regulations of controlled medicines:

- Individuals dispensing the medication must be licensed, either by virtue of their professional license or through a special licensing procedure;
- The medications may only be transferred between authorized institutions or persons;
- The medications can only be dispensed to a patient upon a medical prescription; and
- Records on the movement of these medications are kept for no less than two years.¹⁶⁰

The Single Convention specifically allows countries to put in place additional requirements, including a special prescription form for controlled medications. However, countries have a dual obligation with respects to these medicines: they must ensure their adequate availability for medical and scientific use while preventing their misuse and diversion.¹⁶¹ Countries must take care that any requirements beyond those specified in the 1961 Single Convention do not unnecessarily impede medical access.¹⁶²

¹⁵⁹ INCB, "Report 2014," 2015, pp. 3-4,

https://www.incb.org/documents/Publications/AnnualReports/AR2014/English/AR_2014.pdf.

¹⁶⁰ ECOSOC, "Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol amending the Single Convention on Narcotic Drugs, 1961," arts. 30(1)(b)(i), 30(1)(b)(ii), 30(2)(b)(i), 34 (b).

¹⁶¹ INCB, "Report of the International Narcotics Control Board on the Availability of Internationally Controlled Drugs: Ensuring Adequate Access for Medical and Scientific Purposes," 2011, p. iii, http://www.incb.org/documents/Publications/AnnualReports/AR2010/Supplement-AR10_availability_English.pdf (access May 15, 2015).

¹⁶² WHO, "Cancer Pain Relief," p. 9, <http://whqlibdoc.who.int/publications/9241544821.pdf>.

International human rights standards also require that countries ensure that opioid analgesics that are included in the WHO Model List of Essential Medicines are available and accessible. As manufacturing, prescribing, and dispensing controlled medicines is subject to strict regulation by governments, states have an obligation to ensure these regulations do not unnecessarily restrict patient access to them for medical purposes. Regulations that arbitrarily impede procuring and dispensing these medications for medical purposes can violate the right to health.

The Moroccan government has clearly identified increasing access to opioid analgesics as a priority. The SHS contains a specific action point for “training and provision of information to healthcare personnel and the fight against morphineophobia.”¹⁶³ This point closely mirror measures called for in the NCPCP.¹⁶⁴

However, the availability and accessibility of opioid analgesics remains very limited. Our research found that most regional oncology centers and some pharmacies in their immediate vicinity have morphine available and that at least some physicians could prescribe them.¹⁶⁵ However, visits to four regions found that few secondary care facilities had oral morphine; that doctors there did not have special prescription forms to prescribe opioids; and that pharmacies did not stock them.

Analysis of Regulatory Framework

We analyzed in detail Morocco’s regulations on opioid analgesics and their application in practice to determine to what extent they contribute to the limited availability of these medications.

In 2013, Morocco changed its controlled substance law to increase the number of days a prescription for an opioid analgesic can cover from 7 to 28 days, removing a key barrier to the

¹⁶³ Ministry of Health, “Sectoral Strategy for Health 2012-2016” (“Strategy Sectorielle de Santé 2012-2016”), action 80, <http://www.sante.gov.ma/Docs/Documents/secteur%20sant%C3%A9.pdf>.

¹⁶⁴ Ministry of Health and Lalla Salma Foundation, “National Cancer Prevention and Control Plan” (“Plan Nationale de Prévention et de Contrôle Du Cancer”), measures 63-64, http://www.contrelecancer.ma/site_media/uploaded_files/PNPCC_-_Axes_strategiques_et_mesures_2010-2019.pdf.

¹⁶⁵ Based on interviews conducted with medical personal at four regional oncology centers.

availability of these medicines.¹⁶⁶ The seven-day limitation meant that patients who required opioid analgesics or their relatives had to travel to their physician every single week to obtain and fill a new prescription. Human Rights Watch's 2011 report on the global state of palliative care identified this regulatory requirement as an important barrier to opioid access.¹⁶⁷

Our research shows that Morocco's current regulations go beyond the requirements of the 1961 Single Convention on Narcotic Drugs. Although additional administrative requirements by definition create extra hurdles for the use of these medicines, we did not find that they imposed an excessive burden for physicians or pharmacists, especially those working within the public healthcare system.

A Moroccan law from 1922, from when the country was a French protectorate, still governs the handling, prescribing, and dispensing of opioid analgesics. Under the law, only doctors are allowed to prescribe opioids, although all physicians can obtain prescribing rights.¹⁶⁸

Special Prescription Forms: Moroccan law requires that all outpatient prescriptions for opioids be written on special prescription pads.¹⁶⁹ While the Single Convention specifically allows countries to require their use, the WHO has noted that requirements for special prescription forms increases the administrative burden both for healthcare workers and drug control authorities.¹⁷⁰ It has stated that this problem is “compounded if forms are not readily available, or if health professionals need to pay for them.” It recommends that countries “ensure that this system does not impede the availability and accessibility of controlled medicines.”¹⁷¹

¹⁶⁶ Dahir portant promulgation de la loi n° 92-12 modifiant l'article 34 du dahir du 12 rabii II 1341 (2 décembre 1922) portant règlement sur l'importation, le commerce, la détention et l'usage des substances vénéneuses, no. 1-13-56 du 8 chaabane 1434 of 2013, art. 34, <http://adala.justice.gov.ma/production/html/Fr/183968.htm> (accessed May 15, 2015).

¹⁶⁷ Human Rights Watch Report, *Global State of Pain Treatment: Access to Palliative Care as a Human Rights* (New York: Human Rights Watch, 2011), p. 51, <http://www.hrw.org/sites/default/files/reports/hhro511W.pdf>.

¹⁶⁸ Jim Cleary, et al., “Formulary Availability and Regulatory Barriers to Accessibility of Opioids for Cancer Pain in the Middle East: A Report from the Global Opioid Policy Initiative,” *Annals of Oncology*, vol. 24, suppl. 11, 2013, p. xi54, http://annonc.oxfordjournals.org/content/24/suppl_11/xi51.full.pdf+html (accessed May 15, 2015).

¹⁶⁹ Arrête pris en application de l'article 34 du dahir du 2 décembre 1922 portant règlement sur l'importation, le commerce, la détention et l'usage des substances vénéneuses, June 21, 1955.

¹⁷⁰ ECOSOC, “Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol amending the Single Convention on Narcotic Drugs, 1961,” art. 30(2)(b)(ii).

¹⁷¹ WHO, “Ensuring balance in national policies on controlled substance: Guidance for availability and accessibility of controlled medicines,” 2011, p. 28, http://whqlibdoc.who.int/publications/2011/9789241564175_eng.pdf?ua=1 (accessed May 15, 2015).

Physicians must obtain the special prescription pad, called a “carnet à souche,” from the Ministry of Health’s Department of Medicines and Pharmacy. Importantly, physicians can apply for the special prescription pad by mail rather than having to go in person. The Department of Medicines and Pharmacy can also issue two prescription pads at a time, each containing 50 scrips. The pad must be returned to the Ministry of Health before a new one can be obtained, but the fact that physicians are allowed to have two prescription pads at a time helps minimize the risk of a physician being left without prescription forms for opioid analgesics during the application process.¹⁷²

Physicians at several tertiary level public hospitals told Human Rights Watch that the process for obtaining the special prescription pads was relatively easy and was most often carried out by the hospital administrators on their behalf. Significantly, many of the public regional oncology centers order numerous prescription pads at a time, making them readily available.¹⁷³

The process for obtaining special prescription pads is a larger obstacle for physicians outside the public healthcare system. Unlike public physicians, private physicians must make their initial request for a carnet à souche through an intermediary: the president of The National Order of Doctors, a professional association. The president, in turn, must make a written request to the Ministry of Health.¹⁷⁴ According to Dr. Mati Nejmi, who has been working in private practice since 2013, this process can take over a month.¹⁷⁵ Although private physicians can obtain subsequent prescription pads by writing directly to the Ministry of Health, the initial process may act as a deterrent.

In 2014, the Ministry of Health dispensed 409 special prescription pads, 310 to public physicians and 99 to private physicians.¹⁷⁶ Human Rights Watch does not know how many individual physicians have a carnet à souche but given that many use more than one per year it is likely to be substantially lower than 409.

¹⁷² Arrête pris en application de l'article 34 du dahir du 2 décembre 1922 portant règlement sur l'importation, le commerce, la détention et l'usage des substances vénéneuses, June 21, 1955, art. 5; Human Rights Watch interview with Dr. Hamza Slimani, Anesthesiology Resident, Rabat, January 10, 2015.

¹⁷³ Letter from Dr. Abdelali Belghiti Alaoui, secretary general, Ministry of Health, to Human Rights Watch, June 4, 2015.

¹⁷⁴ Ibid.

¹⁷⁵ Human Rights Watch interview with Dr. Mati Nejmi, September 29, 2014.

¹⁷⁶ Letter from Dr. Abdelali Belghiti Alaoui, secretary general, Ministry of Health, to Human Rights Watch, June 4, 2015.

Morocco has recently made significant progress in increasing the reach of opioid prescription privileges—the number of pads distributed increased by 32 percent between 2013 and 2014. However, only a small fraction of the approximately 20,500 physicians in Morocco have them,¹⁷⁷ making it problematic for patients to find a doctor who even has the ability to prescribe opioids.

Regulations on Opioid Analgesics for Pharmacies: Under Moroccan law, any pharmacy can stock opioid analgesics.¹⁷⁸ However, they must comply with a number of regulatory requirements.¹⁷⁹ Pharmacists described requirements to keep detailed records of any purchases and sales in several special log books, one containing detailed descriptions of all sales, another recording current stock, and a third for purchases of controlled medicines.¹⁸⁰

Each book must be separately purchased, in-person (by the pharmacist or a representative), from a different organization—The National Council of Pharmacists, the Regional Council of Pharmacists, and the Union of Pharmacists—although these are all located in the same building in Rabat. Pharmacists must also pay for the books, which range from 200 to 500 MAD (US\$21 to \$53).¹⁸¹ The three books must all be kept for up to 10 years for possible government audits.¹⁸²

¹⁷⁷ WHO, “World Health Statistics: 2013,” 2013, pp. 120-127,

http://apps.who.int/iris/bitstream/10665/81965/1/9789241564588_eng.pdf?ua=1 (accessed March 23, 2015).

¹⁷⁸ Jim Cleary, et al., “Formulary Availability and Regulatory Barriers to Accessibility of Opioids for Cancer Pain in the Middle East,” p. xi56.

¹⁷⁹ Dahir portant règlement sur l'importation, le commerce, la détention et l'usage des substances vénéneuses, no. 12 rebia II 1341 of 1922, art. 26.

¹⁸⁰ Human Rights Watch interview with Dr. Laghdaf Rhaouti, chief pharmacist at Pharmacie Rhaouti, Rabat, January 14, 2015.

¹⁸¹ Human Rights Watch interview with a representative of the National Council of Pharmacists; Human Rights Watch interview with a representative of the Regional Council of Pharmacists; Human Rights Watch interview with a representative of the Union of Pharmacists.

¹⁸² Dahir du 12 rebia II 1341., arts. 30, 32.

INCREASING ACCESS TO OPIOID ANALGESICS: COLOMBIA AND VIETNAM

A dearth of pharmacies stocking oral morphine is a major challenge in many countries. While one pharmacist in Morocco told us he carries morphine because he feels it is his “professional obligation” to ensure the public has access to the medication, the administrative requirements, low demand, concerns about potential misuse or diversion, and the potential for scrutiny from law enforcement deter many others from stocking it.

Several countries have actively tried to address this issue. In Colombia, for example, intensive engagement between the government, NGOs, and academics led to a revised regulation for regional medicines procurement in 2008. Under that regulation, all 32 Colombian states must have at least one place where opioids are guaranteed to be in stock at all times.¹⁸³ This commitment to opioid availability was solidified in article eight of Colombia’s recently passed palliative care law.¹⁸⁴ Following these and other efforts to increase access to palliative care in Colombia, opioid consumption has increased dramatically. Between 2006 and 2012, the government reported a 270 percent rise in opioid consumption¹⁸⁵

Vietnam has successfully undertaken similar efforts to increase access to palliative care and pain treatment. In 2005, its Ministry of Health launched a palliative care initiative and created a working group on palliative care, which included the ministry, physicians, and international experts.¹⁸⁶

Based on the working group’s findings, the Ministry of Health implemented educational and regulatory reforms beginning in 2006. Significantly, in 2008, the Ministry of Health eased a number of key regulatory barriers to accessing opioids: the maximum daily opioid dose was abolished; the opioid prescription period was increased from 7 to 30 days; assistant doctors in remote areas were given authority to obtain a license to prescribe morphine; and district hospitals and commune health posts were authorized to prescribe and dispense morphine.¹⁸⁷

Similar to Colombia, the new regulations also specify that opioids should be available in each district

¹⁸³ Marta Leon, et al., “Integrating Palliative Care in Public Health: The Colombian Experience Following an International Pain Policy Fellowship,” *Palliative Medicine* (2011), p.3,

http://www.painpolicy.wisc.edu/sites/www.painpolicy.wisc.edu/files/Leon_2011_Integrating%20palliative%20care_o.pdf (accessed May 15, 2015); Marta Leon, et al., “Improving the Availability of and Access to Opioids in Columbia: Description and Preliminary Results of an Action Plan for the Country,” *Journal of Pain and Symptom Management*, vol. 28, no. 5 (2009), [http://www.jpmsjournal.com/article/S0885-3924\(09\)00705-2/pdf](http://www.jpmsjournal.com/article/S0885-3924(09)00705-2/pdf) (accessed May 15, 2015).

¹⁸⁴ Pain Policy, “Celebrating Success: A Palliative Care Law for Colombia,” <https://painpolicy.wordpress.com/2014/10/23/celebrating-success-a-palliative-care-law-for-colombia/> (accessed March 11, 2015).

¹⁸⁵ INCB, “Narcotic Drugs: Estimated World Requirements for 2009, Statistics for 2007,” 2008, p. 236, https://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2008/Narcotics_drugs_publication2008.pdf (accessed May 15, 2015); Treat the Pain, “Colombia—Treat the Pain: A Country Snapshot,” 2014, <http://treatthepain.org/Assets/CountryReports/Colombia.pdf> (accessed March 11, 2015).

¹⁸⁶ Eric L. Krakauer, “Vietnam’s Palliative Care Initiative: Successes and Challenges in the First Five Years,” *Journal of Pain and Symptom Management*, vol. 40, no. 1 (2010), [http://www.jpmsjournal.com/article/S0885-3924\(10\)00360-X/pdf](http://www.jpmsjournal.com/article/S0885-3924(10)00360-X/pdf) (accessed May 15, 2015).

¹⁸⁷ Human Rights Watch interview with Dr. Eric Krakauer, November 3, 2009.

and charge hospital pharmacies with providing oral morphine to outpatient's when it is not otherwise available.¹⁸⁸ Following these and other efforts to increase access to palliative care in Vietnam, opioid consumption increased by over 400 percent between 2005 and 2012.¹⁸⁹

Despite the complexity of the process, most pharmacists Human Rights Watch interviewed said they did not feel these requirements were unnecessarily burdensome. Interviews with 16 private pharmacies in 6 cities, 14 of whom did not stock morphine, suggested that the regulatory requirements were not the primary reason why pharmacies did not to carry the medication. In fact, a number of pharmacists said they had all the necessary books to buy and dispense morphine but did not carry it because of concerns about drug dependence, potential misuse, and a lack of demand for the medication. The pharmacists who did carry and regularly dispense opioids felt that clientele misuse could be handled through proper administration, but did echo some of the economic concerns raised by other pharmacist, including low-profit margins and demand.¹⁹⁰

Dr. Laghdaf Rhaouti, for example, the owner of a pharmacy outside the National Oncology Institute that stocks oral morphine, explained to Human Rights Watch why he carries morphine despite its low profit margins:

I carry morphine because it is my professional obligation.... It is a humanitarian act.... As a pharmacist isn't this my job? As a human being, isn't this my conscience?... I don't just think of the profit, I think of the public need for these medications.¹⁹¹

However, the vast majority of pharmacies choose not to carry these medications, and the dearth of them in small cities is a major barrier to the use of these medications. To fulfill the

¹⁸⁸ Human Rights Watch email correspondence with Dr. Eric Krakauer, April 4, 2015. According to Krakauer's contacts in Vietnam, however, the requirement that hospital pharmacies stock opioids when they are not otherwise available in the district is not currently being enforced.

¹⁸⁹ INCB, "Narcotic Drugs: Estimated World Requirements for 2009, Statistics for 2007," p. 236, https://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2008/Narcotics_drugs_publication2008.pdf; Treat the Pain, "Vietnam—Treat the Pain: A Country Snapshot," 2014, <http://www.treatthepain.org/Assets/CountryReports/Viet%20Nam.pdf> (accessed March 11, 2015).

¹⁹⁰ Human Rights Watch interview with Dr. Laghdaf Rhaouti, Rabat, January 14, 2015; Human Rights Watch interview with Mohammed Jamal Zinber, head pharmacist at Pharmacie Rabat-Ville, Rabat, January 15, 2015.

¹⁹¹ Human Rights Watch interview with Dr. Laghdaf Rhaouti, Rabat, January 15, 2015.

right to health, the government has a duty to ensure this essential medication is available to patients, even if market forces make it unattractive for private pharmacies to carry.

Opiophobia and Misunderstandings

Numerous interlocutors identified fear of opioid analgesics and a lack of training in their use as the main reasons for the limited availability of these medicines in much of the country. The government itself also identified this as a significant barrier in the Sectoral Health Strategy and the National Cancer Prevention and Control Plan.¹⁹²

Many doctors and hospital administrators we interviewed at secondary care facilities said they did not have special prescription forms because they believed opioids were addictive and could only be prescribed by specialists or at tertiary care facilities.¹⁹³ In most of these facilities, morphine was used exclusively by anesthesiologists for surgical procedures.

Fear of and misconceptions about morphine and other opioid analgesics may not be surprising given that the law regulating them is called the Law on the Regulation of Import, Commerce, Holding and Use of *Poisonous* Substances (emphasis added).¹⁹⁴ Under the law, opioid analgesics are included in a schedule called “Table B Poisonous Substances.” While Morocco shares this labeling practice with some other Francophone countries,¹⁹⁵ many Francophone countries use the term narcotics (*stupéfiants*),¹⁹⁶ the designation in the Single Convention.¹⁹⁷

¹⁹² Ministry of Health, “Sectoral Strategy for Health 2012-2016” (“Strategy Sectorielle de Santé 2012-2016”), action 80, <http://www.sante.gov.ma/Docs/Documents/secteur%20sant%C3%A9.pdf>.

¹⁹³ Based on interviews conducted at eight secondary care facilities in eight cities in four regions. None of the hospitals visited were currently providing oral morphine.

¹⁹⁴ Dahir portant règlement sur l'importation, le commerce, la détention et l'usage des substances vénéneuses, no. 12 rebia II 1341 of 1922.

¹⁹⁵ Tunisia: Portant réglementation des substances vénéneuses, law no. 69-54 of 1969, <http://faolex.fao.org/docs/pdf/tun93217.pdf> (accessed June 29, 2015). France: The relevant portion of France's controlled substance regulations can be found here:

http://www.legifrance.gouv.fr/affichCode.do;jsessionid=9C2A8530885827DD24E8C492FB33299A.tpdila24v_2?idSectionTA=LEGISCTA000006171376&cidTexte=LEGITEXTo00006072665&dateTexte=20150626 (accessed June 29, 2015).

¹⁹⁶ Algeria: Fixant les modalités de prescription et de dispensation de l'ordonnance des médicaments contenant des substances classées comme stupéfiants, law no. 20 of 2013, <http://www.joradp.dz/FTP/JO-FRANCAIS/2013/F2013067.pdf> (accessed June 29, 2015). Cameroon: Relative au contrôle des stupéfiants, des substances psychotropes et des précurseurs et à l'extradition et à l'entraide judiciaire en matière de trafic des stupéfiants, des substances psychotropes et des précurseurs, law no. 97-019 of 1997,

<http://policy.mofcom.gov.cn/GlobalLaw/english/flaw!fetch.action?libcode=flaw&id=6e99a79f-e188-448e-ad59-f9c5d634d168&classcode=200> (accessed June 29, 2015).

¹⁹⁷ ECOSOC, Convention unique sur les stupéfiants de 1961, telle que modifiée par le Protocole de 1972 portant amendement de la Convention unique sur les stupéfiants de 1961, https://www.incb.org/documents/Narcotic-Drugs/1961-Convention/convention_1961_fr.pdf (accessed June 29, 2015).

IMPACT OF COLONIAL-ERA CONTROLLED SUBSTANCE REGULATIONS IN FRANCOPHONE COUNTRIES

In the early 20th century, France adopted stringent regulations on the provision of opioid medications, requiring the use of special prescription pads and limiting each prescription to a seven-day period.¹⁹⁸ It imposed the same regulations on many of its colonies.

Since the late 1980s, France has gradually simplified its regulatory requirements to ensure opioid analgesics were available for pain management and palliative care. In 1999, it eliminated the special prescription pad altogether, allowing prescriptions to be made on widely available secure ordinances, and increased the time limit for prescriptions for opioid analgesics to 28 days.¹⁹⁹ While France has substantially simplified its regulatory requirements, numerous Francophone countries continue to live by the strict regulations they inherited in colonial times.²⁰⁰

Until 2013, Morocco also maintained a seven-day limit on prescriptions for opioid analgesics, meaning patients or their relatives needed to visit their physician every week to get a new prescription, a heavy burden for people with a life-limiting illnesses and their families.²⁰¹ However, in an important move, Morocco removed this legal barrier, increasing the opioid prescription period from 7 to 28 days.²⁰²

Human Rights Watch encourages other Francophone countries that retain this limit to follow Morocco's lead, and review and amend regulations to improve access to these essential medicines.

¹⁹⁸ François Chast, "The Origins of the Narcotics Legislation in France" ("Les origines de la législation sur les stupéfiants en France,") *Histoire Des Sciences Médicales*, vol. XLIII, no. 3 (2009), <http://www.biusante.parisdescartes.fr/sfhm/hsm/HSMx2009x043x003/HSMx2009x043x003x0293.pdf> (accessed May 15, 2015); Code de la Santé Publique, Partie Réglementaire Ancienne, Pharmacie, Substances Vénéneuses, Régime Particulier des Stupéfiants, R5212, R5213 of pre-1988 amendments, <http://www.legifrance.gouv.fr/affichCode.do?idSectionTA=LEGISCTA000006187209&cidTexte=LEGITEXT000006072665&dateTexte=19920909> (accessed May 15, 2015).

¹⁹⁹ Renée Sebag-Lanoë, et al., "Palliative Care in a Long-Term Care Setting: a 25-year French Experience," *Journal of Palliative Care*, vol. 19, no. 3 (2003), p. 209, <http://gerontoprevention.free.fr/articles/palliativecare.pdf> (accessed May 15, 2015); Décret relatif aux substances vénéneuses et à l'organisation de l'évaluation de la pharmacodépendance, modifiant le code de la santé publique, no. 99-246 of 1999, art. 5, xi, <http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT00000393106&fastPos=1&fastReqId=326431723&categorieLien=id&oldAction=rechTexte> (accessed May 15, 2015); Human Rights Watch interview with Dr. Marilene Filbet, November 4, 2014. According to Filbet, secure ordinances are used for prescribing all medications, not just morphine.

²⁰⁰ Our research revealed that Cameroon, Madagascar, Mali, Mauritania, Senegal, and Togo all continue to have the seven-day limit and special prescription forms, and Algeria and Tunisia recently removed the seven-day limit. See, for example, Cameroon's narcotics law: Relative au contrôle des stupéfiants, des substances psychotropes et des précurseurs et à l'extradition et à l'entraide judiciaire en matière de trafic des stupéfiants, des substances psychotropes et des précurseurs, no. 97-019 of 1997, arts. 55-68, <http://policy.mofcom.gov.cn/GlobalLaw/english/flaw!fetch.action?libcode=flaw&id=6e99a79f-e188-448e-ad59-f9c5d634d168&classcode=200> (accessed May 15, 2015).

²⁰¹ Human Rights Watch Report, *Global State of Pain Treatment*, p. 52, <http://www.hrw.org/sites/default/files/reports/hhros11W.pdf>.

²⁰² Dahir portant promulgation de la loi n° 92-12 modifiant l'article 34 du dahir du 12 rabii II 1341 (2 décembre 1922) portant règlement sur l'Importation, le commerce, la détention et l'usage des substances vénéneuses, no. 1-13-56 du 8 chaabane 1434 of 2013, art. 34, <http://adala.justice.gov.ma/production/html/Fr/183968.htm>.

Designating essential medicines as poisons clearly stigmatizes them and contravenes WHO guidelines on controlled substance policies that urge states to remove terminology in national medicine control policies that has “the potential to confuse the medical use of opioids for pain with drug abuse or drug dependence.”²⁰³

Availability of Other Opioid Analgesics

Many doctors and pharmacists noted that alternatives to morphine, such as oxycodone and methadone, were not available for pain treatment in Morocco. Methadone is available to treat opioid dependence but not for pain management. As a result, physicians have no alternatives to morphine which complicates the management of patients who do not tolerate the medication or whose pain does not respond to it. One medical oncologist commented:

Not having a range of pain medications is also a problem if a patient has intolerance or side effects with morphine, such as nausea or dizziness. We have morphine, so we can treat severe pain, but we have a problem if we need to rotate to another pain medicine.²⁰⁴

Oxycodone is included in the WHO’s Model List of Essential Medicines’ section on pain and palliative care as an alternative to morphine. Methadone is only included in the section on substance-use disorders but is frequently used in pain management in many countries.²⁰⁵

Moreover, doctors noted that oral liquid morphine (*forme buvable* in French) is not available in Morocco. This complicates administration to patients who have trouble swallowing or uncontrollable nausea, neither of which is uncommon in palliative care patients. Dr. Hessissen, the pediatric oncologist, noted that this is a problem in treating children with pain: “Small children can’t swallow pills. [We] give them codeine instead.”²⁰⁶ The WHO removed codeine from its clinical guideline on treatment of persistent pain in children in 2012 because of safety and efficacy concerns.²⁰⁷

²⁰³ WHO, “Achieving Balance in National Opioids Control Policy,” guideline 14, p. 22, http://whqlibdoc.who.int/hq/2000/who_edm_qsm_2000.4.pdf.

²⁰⁴ Human Rights Watch interview with a medical oncologist (name withheld), regional oncology center, January 26, 2015.

²⁰⁵ WHO, “WHO Model List of Essential Medicines,” 2013, http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1 (accessed May 15, 2015).

²⁰⁶ Human Rights Watch interview with Dr. Laila Hessissen, Rabat, September 30, 2014.

²⁰⁷ WHO, “WHO Guidelines on the Pharmacological Treatment of Persisting Pain in Children with Medical Illnesses,” 2012, p. 39, http://whqlibdoc.who.int/publications/2012/9789241548120_Guidelines.pdf (accessed March 31, 2015).

AVAILABILITY OF NEUROPATHIC PAIN MEDICATIONS

Neuropathic pain (NP) is pain caused by a lesion or disease affecting the nervous system.²⁰⁸ Like non-neuropathic pain, NP is common among individuals with chronic illnesses, including people with HIV, diabetes, and multiple sclerosis.²⁰⁹ NP is “associated with significant decreases in quality of life and socioeconomic well-being, sometimes even more so than non-neuropathic chronic pain.”²¹⁰

Because NP differs from non-neuropathic pain, different medications are required to treat it. Significantly, strong opioids are not recommended as a first-line treatment for NP. In 2015, a systematic review by the International Association for the Study of Pain (IASP) Special Interest Group on Neuropathic Pain (NeuPSIG) recommended 15 key medications to treat NP, grouped in 6 categories.²¹¹

To effectively treat NP in all patients, doctors need access to at least one medication in each of these categories. This provides physicians alternatives, should a patient fail to respond to an available medication, as is common when treating NP.²¹²

A comparison of the Moroccan essential medicine list and AMO and RAMED’s reimbursable medicines list to the medications identified in the NeuPSIG study, however, reveals a number of important differences. Significantly, the Moroccan list is missing two full categories of medications: serotonin noradrenaline reuptake inhibitors (SNRIs) and alpha-2-delta antagonists. Both categories are recommended as first-line treatment for NP. While the reimbursable medicines list includes SNRIs, it is also missing alpha-2-delta antagonists (see Appendix I for details).

²⁰⁸ The definition of Neuropathic Pain from the International Association for the Study of Pain (IASP) can be found here: <http://www.iasp-pain.org/Education/Content.aspx?ItemNumber=1698&navItemNumber=576#Neuropathicpain> (July 25, 2014).

²⁰⁹ Peter R. Kamerman, et al., “World Health Organization Essential Medicines Lists: Where are the Drugs to Treat Neuropathic Pain?,” *Pain*, p. 1, forthcoming, 2015.

²¹⁰ *Ibid.*

²¹¹ Nanna B. Finnerup, et al., “Pharmacotherapy for Neuropathic Pain in Adults: A Systematic Review and Meta-Analysis,” *Lancet Neurology*, vol. 14, p. 168, 2015.

²¹² Peter R. Kamerman, et al., “World Health Organization Essential Medicines Lists,” *Pain*, p. 2, forthcoming, 2015.

IV. Morocco's Obligation to Improve Palliative Care

National Law

Following reforms in 2011, Morocco's Constitution for the first time guarantees a number of economic and social rights to all its citizens, including the right to health.²¹³ Article 31 states, among others:

The State, the public establishments and the territorial collectivities work for the mobilization of all the means available to facilitate the equal access of the citizens to conditions that permit their enjoyment of the right: to healthcare; ... to social protection, [and] to medical coverage....²¹⁴

Article 34 of the constitution adds that particular care must be taken to “provide for the vulnerability of certain categories” of people, including the elderly.²¹⁵

The Sectoral Health Strategy, which includes action points on palliative care and pain treatment, highlights the fact that Morocco's 2011 constitution “makes access to healthcare and medical coverage fundamental rights of all citizens.”²¹⁶ In this context, the SHS specifically adopts a “rights based approach that aims to integrate the right to health provisions contained in the new constitution.”²¹⁷

Right to Health

The International Covenant on Economic Social and Cultural Rights (ICESCR), which Morocco ratified in 1979, specifies in article 12 that everyone has a right “to the enjoyment of the highest attainable standard of physical and mental health.”²¹⁸ The Committee on

²¹³ Institute for Democracy and Electoral Assistance, “The 2011 Moroccan Constitution: A Critical Analysis,” 2012, p. 20, http://www.idea.int/publications/the_2011_moroccan_constitution/loader.cfm?csModule=security/getfile&pageid=56782 (accessed May 15, 2015).

²¹⁴ The Constitution (“La Constitution”), July 29, 2011, art. 31, http://www.amb-maroc.fr/constitution/Nouvelle_Constitution_%20Maroc2011.pdf (accessed May 15, 2015). English translation can be found here: http://www.ancl-radc.org.za/sites/default/files/morocco_eng.pdf (accessed May 15, 2015).

²¹⁵ La Constitution, July 29, 2011, art. 34, http://www.amb-maroc.fr/constitution/Nouvelle_Constitution_%20Maroc2011.pdf.

²¹⁶ Ministry of Health, “Sectoral Strategy for Health 2012-2016” (“Strategy Sectorielle de Santé 2012-2016”), art. 3.2, <http://www.mindbank.info/item/3714> (accessed March 31, 2015).

²¹⁷ *Ibid.*, art. 3.2.1

²¹⁸ International Covenant on Economic Social and Cultural Rights (ICESCR), adopted by General Assembly resolution 2200A (XXI) of 16 December 1966, art. 12, <http://www.ohchr.org/EN/ProfessionalInterest/Pages/ICESCR.aspx> (accessed May 1, 2015).

Economic, Social and Cultural Rights, the body charged with monitoring compliance with the ICESCR, has held that states must make available in sufficient quantity “functioning public health and health-care facilities, goods and services, as well as programmes,” and that these services must be accessible.²¹⁹

Because states have different levels of resources, international law does not mandate the kind of healthcare to be provided. The right to health is considered a right of “progressive realization.” By becoming party to the international agreements, a state agrees “to take steps ... to the maximum of its available resources” to achieve the full realization of the right to health.²²⁰ In other words, high-income countries will generally have to provide healthcare services at a higher level than those with limited resources. But all countries are expected to take concrete steps toward increased services, and regression in the provision of health services will, in most cases, constitute a violation of the right to health.

Notably, the United Nations Committee on Economic, Social and Cultural Rights has also held that there are certain core obligations that are so fundamental that all states must comply with them. While resource constraints may justify only partial fulfillment of some aspects of the right to health, the committee has observed vis-à-vis the core obligations that “a State party cannot, under any circumstances whatsoever, justify its non-compliance with the core obligations..., which are non-derogable.” The committee has identified, among others, the following core obligations:

- To ensure the right of access to health facilities, goods and services on a non-discriminatory basis, especially for vulnerable or marginalized groups;
- To provide essential drugs, as from time to time defined under the WHO Action Programme on Essential Drugs;
- To ensure equitable distribution of all health facilities, goods and services; and
- To adopt and implement a national public health strategy and plan of action, on the basis of epidemiological evidence, addressing the health concerns of the whole population.²²¹

²¹⁹ UN Committee on Economic, Social and Cultural Rights, General Comment No. 14, para 12, [http://www.unhchr.ch/tbs/doc.nsf/\(Symbol\)/40d009901358boe2c1256915005090be?Opendocument](http://www.unhchr.ch/tbs/doc.nsf/(Symbol)/40d009901358boe2c1256915005090be?Opendocument) (accessed May 1, 2015).

²²⁰ ICESCR, art. 2(1).

²²¹ UN Committee on Economic, Social and Cultural Rights, General Comment No. 14, para. 43, [http://www.unhchr.ch/tbs/doc.nsf/\(Symbol\)/40d009901358boe2c1256915005090be?Opendocument](http://www.unhchr.ch/tbs/doc.nsf/(Symbol)/40d009901358boe2c1256915005090be?Opendocument).

The committee lists the obligation to provide appropriate training for health personnel as an “obligation of comparable priority.”²²²

Palliative Care and the Right to Health

Given that palliative care is an essential part of healthcare, the right to health requires that countries take steps to the maximum of their available resources to ensure that it is available. Indeed, the Committee on Economic, Social and Cultural Rights has called for “attention and care for chronically and terminally ill persons, sparing them avoidable pain and enabling them to die with dignity.”²²³ Two different state obligations flow from this:

- A negative obligation to refrain from enacting policies or undertaking actions that arbitrarily interfere with the provision or development of palliative care; and
- A positive obligation to take reasonable steps to ensure the integration of palliative care into existing health services, both public and private, through the use of regulatory and other powers as well as funding streams.

No Interference with Palliative Care

The Committee on Economic, Social and Cultural Rights has stipulated that the right to health requires states to “refrain from interfering directly or indirectly with the enjoyment of the right to health.”²²⁴ States may not deny or limit equal access for all persons, enforce discriminatory health policies, arbitrarily impede existing health services, or limit access to information about health.²²⁵ Applied to palliative care, this obligation means that states may not put in place medicine control regulations that unnecessarily impede the availability and accessibility of essential palliative care medications, such as morphine and other opioid analgesics.

Ensuring Integration of Palliative Care into Health Services

The right to health requires states to take the steps necessary for the “creation of conditions which would assure to all medical service and medical attention in the event of sickness.”²²⁶ The Committee on Economic, Social and Cultural Rights has held that people

²²² Ibid., para. 44.

²²³ Ibid., para. 25.

²²⁴ Ibid., para. 33.

²²⁵ Ibid., para. 33.

²²⁶ ICESCR, art. 12 (2).

are entitled to a “system of health protection which provides equality of opportunity for people to enjoy the highest attainable level of health,”²²⁷ including patients with chronic or terminal illnesses.

The committee has called for an integrated approach to the provision of different types of health services that includes elements of “preventive, curative and rehabilitative health treatment.”²²⁸ It has also held that investments should not disproportionately favor expensive curative health services, which are often accessible only to a small, privileged fraction of the population, rather than primary and preventive healthcare benefiting a far larger part of the population.²²⁹ The same principle applies to palliative care services. Given the large percentage of cancer and other patients who require palliative care services, particularly in low and middle income countries, considerable urgency needs to be given to developing palliative care services for these patients.

Pain Treatment Medication and the Right to Health

As injectable and oral morphine are on the WHO List of Essential Medicines for adults and for children, countries have to provide these medications as part of their core obligations under the right to health.²³⁰ States should make sure these medicines are both available in adequate quantities and physically and financially accessible for those who need them.

In order to ensure availability and accessibility, states have, among others, the following obligations:

- Since regulating the market for controlled medicines like morphine is completely in government hands, states must put in place regulations to ensure an effective procurement and distribution system and create a legal and regulatory framework that enables healthcare providers in both the public and private sector to obtain, prescribe, and dispense these medications. Any regulations that arbitrarily impede

²²⁷ UN Committee on Economic, Social and Cultural Rights, General Comment No. 14, para. 8, [http://www.unhcr.ch/tbs/doc.nsf/\(Symbol\)/40d009901358boe2c125691500509obe?Opendocument](http://www.unhcr.ch/tbs/doc.nsf/(Symbol)/40d009901358boe2c125691500509obe?Opendocument).

²²⁸ *Ibid.*, para. 25.

²²⁹ *Ibid.*, para. 19.

²³⁰ WHO, “Model List of Essential Medicines,” 2013,

http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1. Includes the following opioid analgesics: Codeine tablet: 30mg (phosphate); morphine injection: 10mg (morphine hydrochloride or morphine sulfate) in 1-ml ampoule; oral liquid morphine: 10mg (morphine hydrochloride or morphine sulfate)/5 ml; morphine tablet: 10mg (morphine sulfate); morphine tablet (prolonged release): 10mg; 30mg; 6 mg (morphine sulfate).

the procurement and dispensing of these medications may lead to a violation of the right to health;

- States need to adopt and implement a strategy and plan of action for the roll out of pain treatment and palliative care services. Such strategy and plan of action should identify obstacles to improved services as well as steps to eliminate them;
- States should regularly measure progress made in ensuring availability and accessibility of pain relief medications; and
- The requirement of physical accessibility means that these medications must be “within safe physical reach for all sections of the population, especially vulnerable or marginalized groups.”²³¹ States need to ensure that a sufficient number of healthcare providers or pharmacies stock and dispense morphine and that an adequate number of healthcare workers are trained and authorized to prescribe these medications.

Although the right to health does not require states to offer medications free of charge, financial accessibility means that medications should be “affordable for all.” In the words of the committee:

Payment for health-care services ... has to be based on the principle of equity, ensuing that these services, whether privately or publicly provided, are affordable to all, including socially disadvantaged groups. Equity demands that poorer households should not be disproportionately burdened with health expenses as compared to richer households.²³²

Pain Treatment and the Right to Be Free from Cruel, Inhuman, or Degrading Treatment

The right to be free from torture, cruel, inhuman, or degrading treatment or punishment is a fundamental human right that is recognized in numerous international human rights instruments.²³³ Apart from prohibiting the use of cruel, inhumane, or degrading treatment,

²³¹ UN Committee on Economic, Social and Cultural Rights, General Comment 14, para. 12, [http://www.unhcr.ch/tbs/doc.nsf/\(Symbol\)/40d009901358b0e2c1256915005090be?Opendocument](http://www.unhcr.ch/tbs/doc.nsf/(Symbol)/40d009901358b0e2c1256915005090be?Opendocument).

²³² *Ibid.*, para. 12.

²³³ International Covenant on Civil and Political Rights (ICCPR), adopted December 16, 1966, G.A. Res. 2200A (XXI), 21 U.N. GAOR Supp. (No. 16) at 52, U.N. Doc. A/6316 (1966), 999 U.N.T.S. 171, entered into force March 23, 1976, art. 7; Universal Declaration of Human Rights (UDHR), adopted December 10, 1948, G.A. Res. 217A(III), U.N. Doc. A/810 at 71 (1948); Convention

the right also creates a positive obligation for states to protect persons in their jurisdiction from such treatment.²³⁴

This obligation has been interpreted to include protecting people from unnecessary pain related to a health condition. As Manfred Nowak, then UN Special Rapporteur on torture, cruel, inhuman or degrading treatment or punishment wrote in a joint letter with the UN Special Rapporteur on the right to health to the Commission on Narcotic Drugs in December 2008:

Governments also have an obligation to take measures to protect people under their jurisdiction from inhuman and degrading treatment. Failure of governments to take reasonable measures to ensure accessibility of pain treatment, which leaves millions of people to suffer needlessly from severe and often prolonged pain, raises questions whether they have adequately discharged this obligation.²³⁵

In a report to the Human Rights Council, Nowak later specified that, in his expert opinion, “the de facto denial of access to pain relief, if it causes severe pain and suffering, constitutes cruel, inhuman or degrading treatment or punishment.”²³⁶

Not every case where a person suffers from severe pain but has no access to appropriate treatment will constitute cruel, inhuman, or degrading treatment or punishment. In a 2013 report to the Human Rights Council, UN Special Rapporteur on torture Juan Mendez stated that this will only be the case when the following conditions are met:

- The suffering is severe and meets the minimum threshold required under the prohibition against torture, cruel, inhuman, or degrading treatment or punishment;
- The state is, or should be, aware of the level and extent of the suffering;

against Torture and Other Cruel, Inhuman or Degrading Treatment or Punishment (Convention against Torture), adopted December 10, 1984, G.A. res. 39/46, annex, 39 U.N. GAOR Supp. (No. 51) at 197, U.N. Doc. A/39/51 (1984), entered into force June 26, 1987, art. 16.

²³⁴ See, e.g., the judgment of the European Court of Rights in *Z v United Kingdom* (2001) 34 EHRR 97.

²³⁵ A copy of the letter is available at:

http://www.hrw.org/sites/default/files/related_material/12.10.2008%20Letter%20to%20CND%20fromSpecial%20Rapporteurs.pdf (accessed May 15, 2015).

²³⁶ Human Rights Council, Report of the Special Rapporteur on torture and other cruel, inhuman or degrading treatment or punishment, Manfred Nowak, A/HRC/10/44, January 14, 2009, para. 72,

<http://www2.ohchr.org/english/bodies/hrcouncil/docs/10session/A.HRC.10.44AEV.pdf> (accessed May 15, 2015).

- Treatment is available to remove or lessen the suffering but no appropriate treatment was offered; and
- The state has no reasonable justification for the lack of availability and accessibility of pain treatment.²³⁷

²³⁷ Human Rights Council, Report of the Special Rapporteur on torture and other cruel, inhuman or degrading treatment or punishment, Juan E. Méndez, A/HRC/22/53, February 1, 2013, para. 54, http://www.ohchr.org/Documents/HRBodies/HRCouncil/RegularSession/Session22/A.HRC.22.53_English.pdf (accessed May 15, 2015).

V. Full Recommendations

The introduction of palliative care in Morocco, at major hospitals as well as within in the community, is urgently needed to prevent the unnecessary suffering of thousands of people throughout the country. As a signatory to various international human rights treaties and the UN drug conventions, the government has an obligation to ensure that its citizens have access to affordable palliative care and essential palliative care medications.

The Moroccan government has made significant strides in removing barriers to the development of palliative care. It is thus well positioned to begin implementing the vision articulated in its National Cancer Prevention and Control Plan (NCPCP) and Sectoral Health Strategy (SHS) for the provision of palliative care at all levels of the healthcare system, which would provide enormous benefits to tens of thousands of Moroccans annually. Human Rights Watch believes the following steps are essential for this purpose:

- **Establish general palliative care centers at each of the five university hospitals.** These units should have multidisciplinary teams, including doctors, nurses, and psychologists, all trained in palliative care. This step is of pivotal importance as it would allow Morocco to advance in three important areas:
 - The need to offer palliative care to non-cancer patients;
 - The staff of these services could help teach the palliative care component of Morocco's new medical school curriculum and allow for clinical rotations in palliative care; and
 - These academic institutions could help develop and implement a much-needed palliative care research agenda to determine standards and models of care appropriate for Morocco.
- **Establish palliative care centers at all regional oncology centers and the pediatric oncology hospital in Rabat.** The government should ensure that all currently operational regional cancer centers, as well as ones that are newly opened, have palliative care services. These centers can then serve as the basis for the further decentralization of palliative care. A palliative care unit at the pediatric oncology unit in Rabat could form the basis for developing pediatric palliative care and decentralizing it overtime.

- **Integrate pain treatment and ensure the availability of oral opioid analgesics at secondary care facilities.** The government should ensure that all local, provincial, and regional hospitals have staff adequately trained in the assessment and management of pain and that oral morphine is available. It should ensure that there are pharmacies near these hospitals that stock oral morphine or, alternatively, the hospital pharmacies should dispense it to outpatients.

To implement these steps, we make the following specific recommendations:

In the Area of Integrating Palliative Care into the Structure of the Healthcare System

- **Implement the palliative care and pain treatment measures identified in the SHS and NCPCP.** The Ministry of Health should set benchmarks and timelines for implementing the palliative care measures called for in the SHS and NCPCP and clearly identify the agencies or actors responsible for their implementation. It should set a clear budget for implementing the palliative care component of the SHS. It should do so through an inclusive process with relevant stakeholders. The Ministry of Health should also regularly review progress.
- **Develop and implement a model for palliative care delivery at primary and secondary care facilities.** This should include a model for mobile teams and home-based palliative care.
- **Develop palliative care networks.** The government should develop models and protocols to allow for efficient communication between various palliative care providers at different levels of the healthcare system. The purpose should be to allow patients to receive palliative care at the closest facility that can provide an appropriate level of care.
- **Include palliative care in the next WHO country cooperation strategy.** This step would ensure Morocco benefits from the WHO's current work on implementing the World Health Assembly resolution on palliative care.
- **Implement the WHO Global Action Plan on NCDs and the WHA resolution on palliative care.**

In the Area of Integrating Palliative Care into Healthcare Financing

- **Review RAMED’s coverage of essential medications.** RAMED’s coverage should be reformed with a view of ensuring that medication costs do not constitute an undue barrier to obtaining essential palliative care medications.
- **Reimburse low-income patients for travel expenses.** While the government works to decentralize the provision of palliative care, it should establish a mechanism to support patients who have to travel to access palliative care to ensure that travel costs do not place an excessive burden on them. Measure 68 of the NCPCP recognizes the burden of travel expenses borne by patients and calls for “financial coverage for safe transport from the hospital to the home, and from the home to the hospital.”²³⁸
- **Progressively expand health insurance to Morocco’s uninsured.** In accordance with Morocco's constitution and recommendations of the WHO and World Bank, Morocco should progressively expand health insurance to ensure coverage of those presently lacking coverage.

In the Area of Education

- **Progressively expand the undergraduate, palliative care curriculum to include clinical aspects.** The Ministry of Higher Education and Ministry of Health should develop, jointly with relevant stakeholders, a detailed outline of the palliative care component of the new medical school curriculum. They should also develop and implement a plan for clinical exposure to palliative care for medical students in their 6th and 7th year.
- **Sponsor continuing education trainings in palliative care.** Although the new undergraduate, palliative care curriculum will prepare future doctors to provide palliative care, it is essential that Morocco invest in training the thousands of active doctors who did not benefit from the reformed medical curriculum. The Ministry of Health should sponsor continuing education seminars designed to reach a broad audience of practicing medical personnel.

²³⁸ Ministry of Health and Lalla Salma Foundation, “National Cancer Prevention and Control Plan” (“Plan Nationale de Prévention et de Contrôle Du Cancer”), measure 68, http://www.contrelecancer.ma/site_media/uploaded_files/PNPCC_-_Axes_strategiques_et_mesures_2010-2019.pdf.

- **Develop mandatory, intermediate, clinical training in palliative care.** The Ministry of Higher Education in partnership with relevant public universities should develop a plan to mandate rotations in palliative care units for doctors of certain postgraduate programs, including oncology, internal medicine, anesthesiology, and geriatrics (when added as a medical specialty, as identified in the SHS) to ensure clinical exposure to palliative care.
- **Recognize palliative care as a medical specialty.** Palliative care specialists are essential to providing a full-range of palliative care interventions at tertiary care facilities, coordinating palliative care services within regions, and training other doctors to provide basic palliative care interventions. The Moroccan government should recognize palliative care as a medical specialty, and the Ministry of Higher Education in partnership with relevant public universities should begin developing a curriculum for the specialty.
- **Develop a plan for integrating palliative care into the healthcare worker education system.** The Ministry of Higher Education should convene an inclusive meeting of relevant stakeholders to jointly develop a plan of action for the gradual introduction of palliative care instruction into the curricula for nursing, psychology, and social work programs.

In the Area of Medicine Availability

- **Develop and implement a program to counter misunderstandings and fear around opioid analgesics and to increase the number of physicians with prescription privileges.** The government should actively combat “morphineophobia” by developing trainings in the use of opioid analgesics and outreach programs to ensure that doctors at secondary care facilities have special prescription pads for opioids.
- **Streamline the process for private physicians to obtain prescription privileges.** The process for obtaining opioid prescription privileges is more difficult for physicians working in private hospitals than for those in public hospitals. The Ministry of Health should modify these procedures to ensure that private physicians are not deterred from obtaining special prescription pads.
- **Amend the controlled substances law and any relevant regulations to ensure that opioid analgesics and other medicines are not categorized as poisons.**

- **Ensure the availability of opioid analgesics outside major cities.** The government should ensure that each region in Morocco has pharmacies that stock opioid analgesics. In regions where that is not the case, hospital pharmacies should provide these medications to outpatients.
- **Include in Morocco’s essential medicines list and in the RAMED/AMO list all palliative medications from each medicine category recommended for neuropathic pain by NeuPSIG.**
- **Expand the variety of opioid analgesics available and approved for use in palliative care.** The government should ensure that alternatives to oral tablet morphine, such as liquid morphine, methadone, and oxycodone, are available for patients.
- **Begin utilizing the electronic import/export system for controlled medicines launched by the INCB in March 2015.**²³⁹ The Ministry of Health informed Human Rights Watch that utilizing this system will require changes to regulatory and administrative procedure, but that it plans to carry out the necessary reforms.²⁴⁰

²³⁹ Information about the programs launch can be found here: https://www.incb.org/incb/en/news/news_2015/izes.html.

²⁴⁰ Letter from Dr. Abdelali Belghiti Alaoui, secretary general, Ministry of Health, to Human Rights Watch, June 4, 2015.

Acknowledgments

Research for this report was conducted by Matthew Simon, New York University School of Law fellow in the Health and Human Rights Division of Human Rights Watch; Joseph Amon, director of the Health and Human Rights Division of Human Rights Watch; Diederik Lohman, associate director of the Health and Human Rights Division of Human Rights Watch; and Laura Thomas, consultant for the Health and Human Rights Division of Human Rights Watch. Matthew Simon wrote the report. Brahim Elansari, research assistant in the Middle East North Africa Division of Human Rights Watch, provided invaluable research and translation assistance. The report was reviewed by Diederik Lohman; Joseph Amon; Aisling Reidy, legal advisor at Human Right Watch; Eric Goldstein, deputy director of the Middle East North Africa Division of Human Rights Watch, and Danielle Haas, senior editor in the Program Office.

Jennifer Pierre, senior associate in the Health and Human Rights Division; Meg Mszyco, associate in the Health and Human Rights Division; and Thierno Adenhof, Jeff Eamon, and Stephanie Martinez, interns in the Health and Human Rights Division of Human Rights Watch, provided invaluable assistance. Translation into French was provided by Hervé Couturier and Peter Huvos. Production assistance was provided by Kathy Mills, Jessie Graham, Pierre Bairin, and Fitzroy Hepkins.

We are deeply grateful to the many palliative care patients in Morocco who, despite being gravely ill, agreed to be interviewed for this report. Without them and their relatives, this manuscript would not have been possible. We are committed to using this report to try to make sure that others who develop life-threatening illness—and pain and other symptoms associated with it—will not have to endure the suffering many of these patients faced.

We are also greatly indebted to the many palliative care advocates and medical professionals in Morocco and elsewhere who helped us conduct our research, understand our findings, and write this report. Their commitment to serving people at the most vulnerable time of their lives is both humbling and inspiring. We are particularly grateful for the assistance of Dr. Mati Nejmi—the former chief of anesthesiology at National Oncology Institute and a pioneer in the effort to bring palliative care to Morocco—whose advocacy and clinical work has improved the lives of thousands of Moroccans.

Appendix: Comparison of Neuropathic Pain Medicines with the WHO and Moroccan Essential Medicines Lists

Medication Category	Medication	WHO Essential Medicines List	Morocco's Essential Medicines List	AMO/RAMED List
First-line Medications				
TCA*	Amitriptyline			
	Clomipramine			
	Desipramine			
	Imipramine			
	Nortriptyline			
SNRI*	Duloxetine			
	Venlafaxine			
α2δ antagonist*	Gabapentin			
	Pregabalin			
Second-line Medications				
Opioid	Tramadol			
Topical	8% Capsaicin			
	5% Lidocaine**			
Strong Opioid Medications				
	Methadone			
	Morphine			
	Oxycodone	Listed as morphine alternative		

* TCA: tricyclic antidepressants; SNRI: serotonin noradrenaline reuptake inhibitors; and α2δ: Alpha-2-Delta.

**Lidocaine was not recorded as being listed on the WHO/RAMED list because its topical formulation was a concentration of less than 5 percent.

Indicates medicine formulation that is not included on list.

Indicates medicine formulation that is included on Morocco's list but is not available in Morocco for neuropathic pain treatment.